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Research in context:  70 
Evidence before this study: Previous epidemiologic studies relating risk factors with 71 
cardiovascular diseases and mortality have been restricted to populations from individual countries 72 
most of which were high income and from North America, Western Europe or China. There are 73 
few prospective data from other middle- or low-income countries, or from other regions of the 74 
world. The Global Burden of Disease (GBD) is a compilation of findings from existing studies, 75 
but it is limited by the fact that relatively little high quality data are available from some regions 76 
of the world, studies included were conducted over different periods of time (and so may not reflect 77 
current patterns of risk factors), used different methods and each study focused only on a limited 78 
number of risk factors. While these are the best data currently available, the reliability of some of 79 
the estimates can be improved by large, prospective studies involving multiple countries from 80 
different continents and at different economic levels, conducted in a standardized manner and 81 
simultaneously assessing the associations of several risk factors with incident diseases and 82 
mortality. 83 
 84 
Added Value of this study: We assessed the associations of risk factors for CVD and mortality 85 
in 155,722 participants enrolled from 21 countries in the Prospective Urban Rural Epidemiology 86 
(PURE) study who did not have a prior history of CVD. Over 70% of the population attributable 87 
fraction (PAF) for CVD and mortality in the overall cohort were attributable to fourteen modifiable 88 
risk factors (behavioural: smoking, diet, physical activity, alcohol consumption, sodium intake; 89 
metabolic: hypertension, lipids, diabetes, abdominal obesity; strength; psychosocial factors: 90 
education and symptoms of depression; and environmental factors: household and ambient air 91 
pollution). Metabolic risk factors were the predominant individual level risk factors for CVD, with 92 
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hypertension being the largest, accounting for 22.3% of the PAF. As a cluster, behavioural risk 93 
factors contributed most to deaths, although the single largest risk factor for death was low 94 
education (PAF of 12.5 %). Household air pollution (PAF of 6.7%) had a moderate impact. 95 
Ambient air pollution (PAF 13.9%) appeared to have a large impact on CVD but this estimate uses 96 
methods that differed from that used with all other risk factors as it was not an individual level risk 97 
factor and so is not comparable. Compared with middle- or high-income countries, a higher 98 
proportion of CVD and deaths in low-income countries. The importance of low education, poor 99 
diet, household air pollution and low strength were largest in middle- or low-income countries. 100 
 101 
Implications of all the available evidence: The majority of CVD and mortality are attributable 102 
to a small number of potentially modifiable risk factors. While some risk factors have large global 103 
impacts (e.g. hypertension, tobacco, low education), the impact of others (e.g. poor diet, household 104 
air pollution) vary by the economic level of countries. There is a need to adapt global health 105 
policies to different groups of countries based on the risk factors of greatest impact in each setting.  106 
 107 
 108 
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 111 
 112 
 113 
 114 
 115 
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Abstract:  116 
Background: Global estimates of the impact of common modifiable risk factors on cardiovascular 117 
disease (CVD) and mortality are largely based on data from separate studies, using different 118 
methodologies. The Prospective Urban Rural Epidemiology (PURE) study overcomes these 119 
limitations by using similar methodology to prospectively evaluate the impact of modifiable risk 120 
factors on CVD and mortality across 21 countries (spanning five continents) at different economic 121 
levels. 122 
 123 
Methods: In a multi-national, prospective cohort study, we examined associations for 14 124 
potentially modifiable risk factors with mortality and major CVD in 155,722 community-dwelling 125 
participants (ages 35-70 years at enrollment) from 21 high-, middle-, or low-income countries 126 
(HIC, MIC or LIC) followed for a median  of 9·5 years. We describe the prevalence, hazard ratios, 127 
and population attributable fractions (PAFs) for CVD and mortality associated with a cluster of 128 
behavioural factors (i.e. tobacco, alcohol, diet, physical activity and sodium intake), metabolic 129 
factors (i.e. lipids, blood pressure, diabetes, obesity), socioeconomic and psychosocial factors (i.e. 130 
education, symptoms of depression), strength, household (solid fuel for cooking) and ambient PM 131 
2·5 air pollution. 132 
 133 
Findings: Mean age of the population was 50·2 years of age, 58·3% were female, 52·6% were 134 
from urban areas, 11·1% from HIC, 65·9% from MIC, and 23·0% from LIC. Over 70% of CVD 135 
cases and deaths in the overall cohort were attributed to modifiable risk factors. Metabolic factors 136 
were the predominant risk factors for CVD (41·2% of the PAF), with hypertension being the 137 
largest (22·3% of the PAF). As a cluster, behavioural risk factors contributed most to deaths 138 
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(26·3% of the PAF), although the single largest risk factor was a low education level (12.5% of 139 
the PAF). Ambient air pollution was associated with 13·9% of the PAF for CVD (although 140 
different statistical methods were used for this analysis). In MIC and LIC, the importance of 141 
household air pollution, poor diet, low education, and low grip strength were larger compared with 142 
HIC. 143 
 144 
Interpretation: The majority of CVD cases and deaths can be attributed to a small number of 145 
common, modifiable risk factors. While some factors have extensive global impacts (e.g. 146 
hypertension, education), others (e.g. household air pollution, poor diet) vary by a country’s 147 
economic level. Health policies should focus on risk factors that have the greatest effects on 148 
averting CVD and death globally, with additional emphasis on risk factors of greatest importance 149 
in specific groups of countries. 150 
Funding: See acknowledgements. 151 
Key Words: Cardiovascular disease, mortality, risk factors 152 
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1 INTRODUCTION: 163 
It is estimated that 55 million deaths occurred in the world  in 2017, of which 17·7 million were 164 
from  cardiovascular disease (CVD).1 2 Documenting the consistency or variations in the 165 
associations between risk factors with CVD and mortality both globally and by countries grouped 166 
by economic levels will help the development of global and context-specific strategies for 167 
prevention. 168 
 169 
Thus far, the most comprehensive global estimates of the associations between risk factors and 170 
adult deaths and CVD are  from the Global Burden of Disease (GBD),  the largest meta-analytic 171 
repository of epidemiologic data relating risk factors to mortality and CVD .1,2 However, estimates 172 
are derived through combining data from diverse studies with differing methods, at differing time-173 
periods, with relatively little data from low- and middle-income countries (LIC and MIC). To 174 
complement, validate and extend information derived from the GBD, large international studies 175 
involving MIC and LIC and employing standardized methods of sampling, measurement of 176 
exposures and outcomes, are needed. For CVD, a few multi-national case-control studies have 177 
provided comparative data on the associations of risk factors with myocardial infarction (MI) and 178 
strokes, but these had a majority of non-fatal events, and are prone to potential biases inherent to 179 
case-control studies (e.g. reverse causality or recall biases).3,4 180 
The Prospective Urban Rural Epidemiology (PURE) study is an attempt to provide standardized 181 
and contemporaneous information across several countries, especially those outside North 182 
America and Western Europe.5 The objectives of this report is to quantify and compare the 183 
associations and population attributable fractions of 14 common modifiable risk factors on CVD 184 
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and mortality. We also report whether these associations vary between groups of countries at 185 
different economic levels. 186 
 187 
2 METHODS: 188 
2.1 Study Design and Participants: PURE was designed to include countries across a broad range 189 
of economic levels, social circumstances and health policies, with a proportionally larger 190 
representation from MIC and LIC. The study’s design has been previously published. In 191 
participating countries, urban and rural communities were selected using pre-specified criteria 192 
(Supplementary Appendix A1).5 Within each community, households and individuals were 193 
selected using sampling strategies to minimize the selection of individuals that could potentially 194 
bias any associations between risk factors and outcomes.5 Socioeconomic characteristics and 195 
mortality rates of the study population are comparable to national statistics from participating 196 
countries.6 This analysis was limited to the first two phases of PURE, which involved 21 countries 197 
between 2003-2014 that completed at least one cycle of follow-up visits. Information on vital 198 
status was available in 98·4%, and information on CVD in 94.1%. Median follow up of the cohort 199 
is 9.5 years. The population included was between 35-70 years of age at enrollment, and without 200 
a prior history of CVD, resulting in 155,722 participants (Supplementary Appendix B, Table 1 and 201 
Figure 1). Countries were categorized into HIC, MIC and LIC based on their World Bank country 202 
income classification at the time of inclusion. The study was approved by local ethics committees 203 
in each center, and all participants provided written informed consent. 204 
2.2 Measurement of Risk Factors:  A detailed summary of each risk factor, its method of 205 
measurement, and its categorization for the calculation of population attributable fractions (PAFs) 206 
are summarized in Supplementary Appendix B, Table 2. Data were collected using standardized 207 
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methods. Baseline data were collected at the community, household, and individual levels. For this 208 
analysis, we evaluated the individual and population level risk associated with 14 potentially 209 
modifiable risk factors. Behavioural risk factors were tobacco use, alcohol consumption, diet 210 
quality, physical activity, and sodium intake. The metabolic cluster of risk factors comprised blood 211 
pressure/hypertension, dysgyleemia/diabetes, non HDL-cholesterol, and obesity (measured using 212 
waist-to-hip ratio [WHR], which was more strongly associated with CVD and mortality than body 213 
mass index [BMI] in PURE and several prior studies).7–9 Education and symptoms consistent with 214 
depression was our primary psychosocial variable of interest. Education was included as our 215 
primary socioeconomic variable of interest as we have previously shown that education was a 216 
stronger socioeconomic predictor of CVD and mortality than wealth or income.10 Grip strength 217 
was measured by JAMAR dynamometer, and has previously been shown to be associated with 218 
CVD and mortality.11 Air pollution was examined both as household ( solid fuels for cooking), 219 
and ambient, which was estimated at the community level, and obtained from integrating 220 
information on particulate matter smaller than 2·5 microns (PM2·5) from a combination of satellite 221 
observations, chemical transport models, and ground level monitoring,12  222 
For overall diet quality, we used a composite diet score which has been replicated in 5 independent 223 
studies and was at least as good, or superior to previous diet risk scores (unpublished data). Non 224 
HDL-C was chosen as our primary lipid value because it had the strongest association with CVD 225 
(Supplementary Appendix B, Table 3). Fasting urinary sodium excretion was estimated using the 226 
Kawasaki formula, and used as a surrogate for sodium intake in 101,609 individuals with available 227 
data.13.  228 
2.3 Outcomes: The primary outcomes for this paper were composite of CVD events (defined as 229 
CV death, myocardial infarction, stroke and heart failure) and mortality. During follow-up, these 230 
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events were collected using standardized case-report forms , reported based on common definitions 231 
and adjudicated. (Supplementary Appendix A2).  232 
 233 
2.4 Statistical analysis:  234 
Categorical variables are summarized as proportions, and continuous variables as means with 235 
standard deviations (SDs). Associations between risk factor and the outcomes were determined 236 
using multivariable Cox frailty models for the entire cohort, and also by countries grouped by 237 
income level. To account for variations in outcomes due to differences between centers, random 238 
intercept effects were included in the models. For the Cox frailty models, proportionality 239 
assumptions were assessed, as was residual heterogeneity after inclusion of the frailty term (i.e. 240 
random intercept effects) into each model (Supplementary Appendix A3). For 12 risk factors 241 
(other than sodium and ambient air pollution), each model was mutually adjusted for all other risk 242 
factors, in addition to age, sex, and urban-rural area. Analyses were conducted on participants with 243 
complete data (Supplementary Appendix B, Table 4). Information on sodium excretion was 244 
available in only two-thirds of the study population, and air pollution was analyzed as a community 245 
level variable. Therefore hazard ratios for these two risk factors were calculated separately from 246 
the other 12 risk factors (Supplementary Appendix A4 and A5). Associations are presented as 247 
hazard ratios with 95% confidence intervals. To estimate the population level risk attributable to 248 
each risk factor (or clusters of risk factors), we calculated average population attributable fractions 249 
using the approach described by Eide and Gefeller, and based on the ‘averisk’ R package 250 
developed by Ferguson et al. (see Supplementary Appendix A6 for methods).14,15 Consistent with 251 
our hazard ratio calculations, PAFs for 12 risk factors, excluding sodium and ambient air pollution, 252 
were calculated together using a single model, while the latter were calculated separately. 253 
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2.5 Role of the funding sources: External funders had no role in study design, data collection, 254 
analysis, interpretation, writing or submitting the report for publication. Four authors (SY, PJ, SR 255 
and SI) had full access to the data, and made the decision to submit for publication 256 
 257 
3 RESULTS: 258 
Characteristics of the study population are summarized in table 1. The mean age of the population 259 
was 50·2 (standard deviation [SD] 9·9) years of age, and 58·3% were female. 52·6% of the 260 
population were from urban areas. During follow up, 10,234 deaths (of which 2917 were due to a 261 
CVD), 7980 incident CVD cases, 3559 MIs, and 3577 strokes occurred. Rates of each outcome 262 
are overall and by groupings of countries by income status are summarized in Supplementary 263 
Appendix B, Table 5. 264 
Of the behavioural risk factors, 20·6% of the study population reported current tobacco use; 4·2% 265 
were consuming moderate and 1·9% were consuming high amounts of alcohol; and 18·5% 266 
reported low physical activity. Mean PURE diet score was 3·9 (SD 1·9); a lower score indicates 267 
worse diet; and mean sodium excretion was 4·7 (SD 1·9) g/day, with 20·9% of the population 268 
consuming >6g/day. 11·3% of the population reported symptoms consistent with depression in the 269 
prior year to enrollment. With respect to metabolic risk factors, 39.4% had hypertension, and 270 
10·2% had diabetes. Mean non-HDL cholesterol was 3·7 (1·0) mmol/L, mean BMI was 25·7 (SD 271 
5·3) and mean waist-to-hip ratio (WHR) was 0·87 (SD 0·1). 272 
 273 
Important variations in baseline characteristics and risk factors were observed between populations 274 
across groups of countries categorized by income (table 1). MIC and LIC had more individuals 275 
from rural areas compared with HIC. The mean age was lowest in LIC (48·3 years), intermediate 276 
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in MIC (50·6 years) and highest in HIC (51.6 years). Only primary education level or less was 277 
attained in the majority of participants from LICs (54·0%), in  43·8% from MICs, and 13·2% in 278 
HICs. By contrast, the proportion of participants with a college, trade, or university education was 279 
highest in HIC (58·0%), followed by MIC (14·9%) and lowest in LIC (12·7%). A greater 280 
proportion of participants in HIC reported a history of smoking or alcohol consumption compared 281 
with MIC or LIC, although current smoking was higher in MIC and LIC compared to HIC. Diet 282 
quality scores indicated healthiest diet in those from HIC, followed by MIC and then LIC. Sodium 283 
consumption was highest in MIC (driven by higher levels in China, but not other MIC). Of the 284 
metabolic risk factors, mean BMI, WHR, and non-HDL cholesterol levels were highest in HIC, 285 
hypertension prevalence was highest in MIC, and diabetes prevalence was highest in LIC. Grip 286 
strength was highest in HIC, followed by MIC and lowest in LIC. Household air pollution from 287 
solid fuel use was highest in LIC (50·0%), followed by MIC (23·3%), and nearly zero in HIC. 288 
Mean PM 2·5 levels were 20·9, 47·9, and 58·4 µg/m3 respectively in HIC, MIC and LIC. 289 
 290 
Risk of CVD and death associated with 12 individual or household level risk factors: 291 
 Of the behavioural risk factors, tobacco use was the most strongly associated with CVD, followed 292 
by physical activity, and low-quality diet (table 2). Of the metabolic risk factors, hypertension had 293 
the strongest association with CVD, followed by diabetes, elevated non-HDL cholesterol and 294 
increased WHR. Low education levels, depression symptoms, low grip strength, and household 295 
air pollution were also associated with a higher risk of CVD. The risk associated with low 296 
education was highest in LIC; risk with tobacco was highest in HIC; and risk with diabetes was 297 
highest in HIC and LIC (Figure 1a). 298 
 299 
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Of the behavioural risk factors, tobacco use showed the strongest association with death, followed 300 
by high alcohol consumption, low physical activity and poor diet (table 2). Of the metabolic 301 
factors, diabetes was the strongest risk factor for death, followed by hypertension and abdominal 302 
obesity. Compared to the lowest tertile of non HDL-C, higher tertiles were associated with a lower 303 
mortality (however it was associated with a higher risk of CVD mortality [figure 3])..16 Education 304 
and household air pollution were also strongly associated with a higher risk of death. Lower 305 
education and alcohol consumption had the strongest associations with death in LIC, while tobacco 306 
had the strongest association with death in HICs (figure 1b).  307 
 308 
Hypertension was a stronger risk factor for stroke compared with myocardial infarction, whereas 309 
diabetes, non-HDL cholesterol and current tobacco use were stronger risk factors for MI compared 310 
to stroke (figure 2).   311 
 312 
Metabolic risk factors tended to have a stronger association with CV death compared with non-313 
CV death (figure 3).  Elevated non-HDL cholesterol was associated with a higher risk of CV death, 314 
but an apparent lower risk of non-CV death, but this may be due to reverse causality due to lower 315 
lipid values being associated with some chronic diseases. 316 
 317 
 Population attributable risks of 12 individual and household level risk factors with CVD 318 
and mortality 319 
Approximately 71% of the PAF for CVD, 79% for MI, and 65% for stroke were attributed to 320 
individual and household level risk factors ((Figures 4 and 5, and Table 3). Risk factors 321 
contributed to a larger proportion of the PAF for CVD in LIC compared with MIC or HIC (figure 322 
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4). Across all groups of countries categorized by income levels, the largest contribution to CVD 323 
was from the cluster of metabolic factors.   324 
 325 
Hypertension was the largest risk factor for CVD, contributing to 22·3% of its PAF. This was 326 
followed by high non-HDL cholesterol, household air pollution, tobacco use, poor diet, low 327 
education, abdominal obesity, and diabetes (each contributing to between 5-10% of the PAF for 328 
CVD) (figure 5). Other risk factors each contributed less than 5% of the PAF for CVD. High-non 329 
HDL cholesterol was the largest risk factor for MI followed by hypertension, and tobacco use. 330 
Hypertension was the largest risk factor for stroke, followed by household air pollution and poor 331 
diet. 332 
 333 
Approximately 75% of deaths were attributed to individual and household level risk factors, with 334 
the largest impact observed in LIC. (Figures 4 and 6, and table 3).   Behavioural risk factors had 335 
the largest PAF for death overall, but large variations were observed as to which factors were 336 
associated with the highest PAFs between county groups. In HIC, metabolic risk factors 337 
contributed most to deaths, but their relative impact was less in MIC and LIC; while the impacts 338 
of behavioural risk factors, education and household air pollution were higher in MIC and LIC 339 
compared with HIC.  340 
 341 
Low education had the highest PAF for death in the overall population, followed closely by 342 
tobacco use, low grip strength, and a poor diet (each contributing to > 10% of the PAF for death). 343 
Hypertension, household air pollution, and diabetes each contributed between 5-10% of the PAF 344 
for death, while other risk factors contributed to less than 5% the PAF. For CV death, hypertension 345 
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was the risk factor with the highest PAF, with several additional risk factors contributing to > 5% 346 
of its PAF. Tobacco use was the largest risk factor for non-CV death, followed closely by low 347 
education, low grip strength, poor diet and household pollution. Other risk factors contributed to 348 
less than 5% of the PAF for non-CV death.  349 
 350 
High sodium versus CVD and mortality: 351 
Compared to a reference of 4-6g/day, excretion of >6g/day of sodium was associated with a 352 
1·12(95% CI 1·03, 1·22) risk of CVD, 1·16(1·00, 1·34) of MI, 1·09 (0·98, 1·21) of stroke, and 353 
1·18(1·07, 1·29) of death.  Elevated sodium intake accounted for 3·2% of the PAF for CVD, 354 
2·7% for MI, 3·3% for stroke, and 3·9% for death.  355 
 356 
Ambient PM2.5 air pollution vs CVD and mortality: 357 
For each 10 unit increase in outdoor PM2·5 there was a HR of 1·05 (95% CI 1·02-1·08) in the risk 358 
of CVD, with a larger effect with stroke (HR = 1·08 (95% CI 1·05-1·11) than with MI (HR = 1·03 359 
(95% CI 1·00-1·06)) (Table 4).  The association of PM2·5 with overall mortality and non-CV 360 
death were inverse; however, in sensitivity analyses controlling for additional geographic factors 361 
(using a center urban and rural fixed effect) the estimates changed  to increased and null 362 
associations, respectively.  In these analyses, a  10 unit increase  in PM2·5 was associated with a 363 
HR of 1·07 (95% CI: 1·01-1·15) for mortality, 1·13 (95% CI: 1·02-1·55) for CVD mortality, 1·04 364 
(95% CI: 0·97-1·12) for non-CV mortality, 1·11 (95% CI: 1·03-1·19) for CVD events, 1·11 (95% 365 
CI: 1·01-1·21) for MI, and 1·14 (95% CI: 1·02-1·27) for stroke. Ambient PM2·5 air pollution 366 
contributed to 14% of the PAF for CVD, 9% for MI, and 21% of the PAF for stroke. However, the 367 
statistical approach to the calculation of PAF for ambient air pollution (as a community level risk 368 
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factor) differed from that used for the impact of all other risk factors (which were based on 369 
individual level data) and so they are not strictly comparable. 370 
 371 
4 DISCUSSION 372 
Our overall findings indicate that over 70% of CVD cases can be attributed to a small cluster of 373 
modifiable risk factors. The largest proportion of PAF for CVD, stroke and MI globally were 374 
attributed to metabolic risk factors, with hypertension being the largest risk factor for CVD, and 375 
accounting for just over one fifth of the PAF for CVD. Hypertension had a larger impact on stroke 376 
than on MI. After hypertension, 5-10% of the PAF for CVD could be attributable to each of several 377 
metabolic, behavioural and other risk factors. Physical activity, symptoms of depression, and 378 
excess alcohol consumption, each had relatively modest contributions to CVD at the global level.  379 
 380 
Approximately two-thirds of deaths in the study were from non-cardiovascular causes. The 381 
majority of total deaths were associated with low education, behavioural factors (poor diet and 382 
tobacco use), low grip strength, household air pollution, hypertension and diabetes (with other 383 
factors each contributing to <5% of its PAF).  While lower education levels are associated with  384 
greater clustering of adverse health related behaviours,  this association  persists after adjusting  385 
for health behaviours.17  The  association  of education with  mortality is larger than what is 386 
observed with   wealth or income.10 Education influences multiple conditions from childhood 387 
onwards, including exposures to community level factors (such as living or working in healthier 388 
environments), and better access to health and social resources. Our findings are also consistent 389 
with studies which  observed that educational reforms can lead to  reductions in CV and non-CV 390 
related mortality.18  It is therefore likely that with improving education of the population, mortality 391 
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rates from several different conditions will also decline, indicating that investment in education 392 
can have broad health benefits. 393 
 394 
The impact of low grip strength as a risk factor for death was comparable or greater than that of 395 
several conventional risk factors. It is not known whether modifying strength in itself will directly 396 
impact mortality, but addressing the underlying processes (such as frailty) could result in greater 397 
resilience during acute or chronic illnesses, or injury. Consistent with this, in PURE, low grip 398 
strength was strongly associated with higher mortality and case fatality rates after acute illnesses 399 
(independent of multi-morbidity, unpublished data), but had weaker associations with the 400 
development of disease per se.11  A greater understanding of how grip strength influences survival 401 
in people with disease, and learning how these processes can be modified to prolong survival, can 402 
lead to new interventions to reduce mortality.   403 
 404 
The PAFs of high sodium consumption (i.e. >6 g/day) for CVD and mortality in the global cohort 405 
were relatively small (about 3.0%), which is consistent with most studies that have examined the 406 
direct association  of  sodium excretion with  CVD or mortality.13,19–21 We did not incorporate the 407 
data in those with sodium consumption below 4 g/d as they showed higher CVD and mortality 408 
compared to those with sodium between 4 and 6 g/d—and we are uncertain of their implications. 409 
Including those with a sodium below 4 g/d would decrease the overall impact of a strategy of 410 
extreme sodium reduction, Strategies to reduce sodium may have larger benefits in regions where 411 
sodium consumption is high (e.g.  China or Central Asia), or in specific populations who may be  412 
sensitive to the effects of sodium (e.g. those with hypertension).22 Therefore targeted or 413 
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contextually appropriate approaches to reduce sodium intake is preferable to attempting universal 414 
reductions. 415 
 416 
Our findings also highlight the importance of addressing both household and ambient air pollution 417 
to reduce CVD and mortality. Exposure to both forms of air pollution were higher in MIC and 418 
highest in LIC, so it is likely that strategies to reduce air pollution will have the largest impact in 419 
these countries.  Ambient air pollution was primarily associated with a higher risk of CVD, while 420 
household air pollution was associated with higher risks of both CVD and death, which may be 421 
related to the greater levels of pollution when cooking with solid fuels. Our data indicate an 422 
important proportion of deaths globally are attributed to household air pollution, despite essentially 423 
no exposure to solid fuels in HIC. We estimated that 13.9% of CVD cases globally could be 424 
attributed to ambient air pollution, but since it is a community level exposure, we were not able to 425 
make direct comparisons to other risk factors (as the average PAF method generally results in 426 
lower risk estimates). A 10 microgram increase in PM 2·5 is associated with a 3% increase in the 427 
risk of CVD deaths, a 5% increase in CVD events, a 3% increase in MI and a 7% increase in stroke. 428 
To put this in perspective, there is a 2.5 fold difference in PM2.5 between HIC and MIC and 3.7 429 
fold difference between HIC and LIC. Given the pervasiveness of ambient air pollution, if these 430 
relatively modest associations between PM 2·5 and CVD are causal, this would account for a 431 
significant proportion of the differences in CVD rates between HIC and MIC or LIC. 432 
      433 
The comparative impact of some of our risk factors varied between groups of countries by their 434 
economic levels, which could be for several reasons. First, we observed that for some risk factors, 435 
(e.g. smoking, education) associations with CVD or mortality differed between groups of 436 
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countries. For example,  the association of low education with CVD and mortality was  strongest 437 
in MIC and LIC; which may be due to the greater support provided to those with low education in 438 
HICs or greater disparities between those educated and not educated in poorer countries. Second, 439 
the comparative impact of risk factors on CVD or deaths would be expected to vary between 440 
country groups depending on the prevalence of each risk factor, the relative incidences of different 441 
diseases (e.g. MI versus strokes) and the predominant causes of death (e.g. CVD, cancers, or 442 
infections). This also means that the relative impact of different risk factors on specific diseases 443 
and specific causes of death may change over time as the levels of risk factors change or if effective 444 
treatments (e.g. lipid lowering or anti-hypertensive drugs) are more widely used. Third, the relative 445 
frequency of deaths from CVD versus other causes varies between countries at different economic 446 
levels, and so the relative impact of risk factors on total mortality will also vary if the prevalence’s 447 
of risk factors which predominantly affect CV mortality, but not other causes of death, change 448 
over time. 449 
 450 
In HIC, about 70% of CVD cases were attributed to modifiable risk factors (excluding ambient air 451 
pollution), with the largest contributors being metabolic risk factors and tobacco use. This is 452 
consistent with the findings of prior epidemiologic studies conducted in North America and 453 
Europe. Modifiable risk factors also accounted for about 70% of CVD cases in MICs, with 454 
hypertension being the leading risk factor for CVD. While metabolic (i.e. abdominal obesity, 455 
elevated cholesterol) and behavioural (i.e. tobacco use) risk factors remained significant, the 456 
impact of low education was larger in MIC compared with HIC. In LIC modifiable risk factors 457 
accounted for about 80% of CVD cases, with the largest risks attributed to modifiable risk factors, 458 
household air pollution, and poor diet. Household air pollution was the third largest individual risk 459 
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factor for CVD in LIC, likely due to the high prevalence of exposure in these countries. Poor diet 460 
was the leading behavioural risk factor for CVD in LICs, and at least as important as, if not more 461 
than, tobacco use. This is in keeping with a larger proportion of the population with poor diet, and 462 
very low rates of smoking among women, as well as lower risks of CVD and mortality associated 463 
with smoking in LIC.  464 
Approximately 65% of deaths in HIC were attributable to these modifiable risk factors. The largest 465 
contributor to mortality in HIC was tobacco use, likely related to its impact on several non-466 
communicable diseases including CVD, cancer and respiratory disease, as well as the high 467 
prevalence of current or past smoking in both men and women in the population. Hypertension 468 
and abdominal obesity were the next largest risk factors for death in HICs, reflecting the large 469 
contribution of CVD to overall mortality in these counties. Low education was the fourth largest 470 
cause of death in HIC, emphasizing the need to improve education even in HIC. 471 
 472 
 In MIC, about 70% of deaths were attributable to individual level risk factors. The comparative 473 
importance of education was higher in these countries, and it was the third largest individual risk 474 
factor for death, after hypertension and tobacco. About 80% of deaths in LIC were explained by 475 
the modifiable risk factors. Aside from tobacco use and low education, other leading risk factors 476 
for death (poor diet, low grip strength, and household air pollution) had much larger impacts in 477 
LIC compared with MIC or HIC. This highlights the need for direct data from LIC to better guide 478 
prevention efforts in these countries, rather than extrapolating data from HIC. 479 
Our study has some potential limitations. Since our data are based on 21 countries, it may not be 480 
generalizable to all countries. In particular we have no data from West Africa and North Africa or 481 
Australia; the number of participants from the Middle East is modest; and data from LICs are 482 
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predominantly from South Asia with a few African countries. We will attempt to overcome these 483 
limitations by enrolling participants from these regions, or by developing collaborative analyses 484 
with independent cohorts in the future. Second, within countries, recruitment of participants was 485 
from one or two specific provinces, although in some countries (e.g. China, India, Canada, 486 
Malaysia, Turkey, and Colombia) participants were recruited from several provinces. Therefore 487 
the data in PURE from each country should not be taken as applying to the whole population in 488 
these countries. Third, while biases have been minimized in the selection of individuals within a 489 
community, the countries and centers within each country were selected based on feasibility and 490 
the willingness of investigators to participate in a large, long-term cohort study. However, the 491 
inclusion of nearly 900 urban and rural communities, from multiple countries in different regions 492 
of the world, provides substantial diversity of risk factors and contextual variables and makes it 493 
likely that the   the PURE results are more  broadly applicable than most previous studies and so 494 
the results are also likely applicable to many more countries than the 21 included in the study. 495 
Fourth, although the majority of risk factors were derived or supplemented with objective 496 
measures (e.g. blood pressure, lipids, grip strength, anthropometry, ambient air pollution, sodium 497 
excretion), or self-reported based on validated instruments (e.g. physical activity, diet), some 498 
misclassification is possible. We did collect repeat information at 3 and 6 years on the above risk 499 
factors in about 20 to 30% of participants and using this information to correct for regression 500 
dilution biases for continuous variables made the hazard ratios stronger but the same analyses was 501 
not possible for categorical variables and moreover there is no method we are aware of how to 502 
incorporate such measurement errors in the estimations of PAF.Therefore, we present the data 503 
without these corrections, which is likely an underestimate of the associations of several of these 504 
risk factors on CVD and mortality.  Fifth, the only risk factor we report in this paper at the 505 
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community level is ambient air pollution, and it is likely that other community level factors (e.g. 506 
built environment, chemical exposures, noise pollution) and differences in access to health care 507 
have important impacts on CVD and mortality. These will be incorporated in future analyses from 508 
PURE. Finally, only large differences in PAF between risk factors should be taken as evidence 509 
that one risk factor is more important than another. PAF estimates in subgroups (i.e. by disease 510 
type or by country income level) may be more prone to random error, particularly if effect sizes 511 
are modest, which we observed for a few risk factors. In general, when PAFs are within a few 512 
percentages of each other, they should be interpreted as being of similar importance, especially if 513 
the confidence intervals of the estimates also overlap. 514 
 515 
The findings reported in this paper are complementary to other studies on the importance of risk 516 
factors for CVD and mortality. For example, Stringhini et al. observed that socioeconomic status 517 
(defined by occupation) was the third largest risk factor for mortality in a meta-analysis of cohorts 518 
from seven HIC.23 In PURE, low education was the fourth leading risk factor for death in HIC, but 519 
the largest disparities were observed in MIC and LIC, suggesting that  improving education, or 520 
addressing the barriers to health in these populations, should be among the highest health priorities 521 
to reduce premature mortality, particularly in MIC and LIC. Consistent with estimates from the 522 
GBD, we found that that modifiable risk factors account for the majority of deaths globally.2–4  523 
Both studies highlight the large impacts that elevated blood pressure, tobacco use, and poor diet 524 
quality have on mortality at the global level, although our observations also emphasize the need to 525 
consider education and strength as key modifiable factors for improving health. Data such as ours 526 
will help refine future estimates from GBD and other pooled analyses. Further, our findings 527 
indicate that reducing CVD and premature mortality will require both general and context specific 528 
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approaches that target risk factors at the individual (e.g. behavioural and metabolic), community 529 
and environmental levels. While tobacco avoidance, hypertension control and reducing elevated 530 
lipids are important global strategies, substantial additional benefits can be potentially achieved 531 
by addressing socioeconomic factors such as improving education, and reducing environmental 532 
factors such as air pollution.  In addition, strategies that improve household access to clean fuels, 533 
improve strength, and diet quality are likely to have particularly large effects in MIC or LIC, and 534 
need to be considered major health priorities in these countries. Such context specific strategies 535 
are likely to have a greater impact in reducing premature CVD or mortality than global strategies 536 
based mostly on information from HIC. 537 
 538 
In conclusion, PURE indicates that a large proportion of CVD and premature deaths could be 539 
averted by targeting a few modifiable risk factors. While some risk factors warrant global policies 540 
(e.g. hypertension control, tobacco control or improved education), the importance of several risk 541 
factors varies between countries at different economic levels, highlighting the need for additional 542 
context specific priorities for prevention of premature CVD and deaths. 543 
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Figure Legend: 662 
Figure 1a and b: Variations in the associations between 12 modifiable risk factors and a) 663 
cardiovascular disease and b) death in high-, middle-, and low-income countries. HDL = high 664 
density lipoprotein, HIC = high income countries, HR = hazard ratio, LIC = low income countries, 665 
MIC = middle income countries. 666 
 667 
Figure 2: Risk of myocardial infarction and stroke associated with 12 modifiable risk factors. 668 
HDL = high density lipoprotein, HR = hazard ratio, MI = myocardial infarction. 669 
 670 
Figure 3: Risk of CV death and Non-CV death associated with 12 individual or household 671 
level modifiable risk factors. CV = cardiovascular, HDL = high density lipoprotein, HR = hazard 672 
ratio, MI = myocardial infarction. 673 
 674 
Figure 4: Population attributable fractions for CVD and mortality associated with 12 675 
individual or clusters of modifiable risk factors. Data are derived from PAF estimates 676 
summarized in table 4. Estimates for individual risk factors were truncated at a lower limit of 0, 677 
as this is the lowest threshold to demarcate a relationship with increased risk. HDL = high 678 
density lipoprotein, HIC = high income countries, LIC = low income countries, MIC = middle 679 
income countries, PAF = population attributable fraction 680 
 681 
 682 
 683 
 684 
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Figure 5: Population attributable fractions for 12 individual and population level risk 685 
factors with CVD, MI and Stroke. Estimates for individual risk factors were truncated at a 686 
lower limit of 0, as this is the lowest threshold to demarcate a relationship with increased risk. 687 
Depress = symptoms of depression, HDL = high density lipoprotein, MI = myocardial infarction, 688 
PAF = population attributable fraction.  689 
 690 
Figure 6: Population attributable fractions for individual risk factors and all-cause 691 
mortality, CV deaths and non-CV death. ** Not included as PARs and 95% confidence 692 
intervals were negative, but potentially related to reverse causality. Estimates for individual risk 693 
factors were truncated at a lower limit of 0, as this is the lowest threshold to demarcate a 694 
relationship with increased risk. CV = cardiovascular, Depress = symptoms of depression, HDL 695 
= high density lipoprotein, PAF = population attributable fraction.   696 
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0 0.5 1 1.5 2 2.5 3
CARDIOVASCULAR DISEASE
HIC MIC LIC
*−Pvalue for testing interaction between country income  and each exposure category
   
 
Tobacco Use
Never
Former
Current
Alcohol Use
Never
Former
Current Low
Current Moderate
Current High
Diet Score
Score >=5
Score 3−4
Score <=2
Physical Activity
High Active
Mode Active
Not Active
Hypertension
No
Yes
Diabetes
No
Yes
Non−HDL Cholesterol
Non−HDL <= 3.2
Non−HDL 3.2−4.0
Non−HDL > 4.0
Waist to Hip Ratio
Low
High
Education
Trade/Coll/Univ
Sec/HgherSec
None/Prim/Unk
Depression
No
Yes
Grip Strength
Quintile 5
Quintile 4
Quintile 3
Quintile 2
Quintile 1
Household Air Pollution
Clean
Solid Fuel
HR
(95%CI) 
 
1
1.45(1.13,1.87)
2.58(1.92,3.47)
1
1.00(0.65,1.54)
0.80(0.59,1.09)
0.56(0.38,0.84)
1.37(0.91,2.06)
1
1.10(0.86,1.41)
1.36(0.88,2.12)
1
1.31(1.05,1.64)
1.13(0.79,1.62)
1
1.37(1.09,1.71)
1
1.72(1.29,2.28)
1
0.85(0.64,1.12)
0.80(0.62,1.03)
1
1.18(0.92,1.52)
1
0.94(0.74,1.21)
1.68(1.25,2.26)
1
1.30(0.98,1.71)
1
1.09(0.82,1.45)
1.11(0.81,1.53)
1.06(0.73,1.53)
1.75(1.22,2.52)
1
1.00(1.00,1.00)
0 0.5 1 1.5 2 2.5 3
 
HR
(95%CI) 
 
1
1.26(1.13,1.41)
1.84(1.67,2.02)
1
1.24(1.08,1.43)
0.88(0.79,0.98)
0.86(0.72,1.03)
1.12(0.91,1.39)
1
1.08(0.99,1.18)
1.16(1.04,1.29)
1
1.21(1.11,1.31)
1.37(1.24,1.51)
1
1.38(1.28,1.50)
1
1.66(1.51,1.83)
1
0.89(0.81,0.97)
0.93(0.84,1.02)
1
1.12(1.04,1.21)
1
1.06(0.92,1.22)
1.36(1.18,1.57)
1
1.30(1.15,1.47)
1
1.06(0.93,1.21)
1.10(0.96,1.25)
1.24(1.09,1.41)
1.48(1.29,1.70)
1
1.20(1.08,1.34)
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1
1.03(0.81,1.30)
1.36(1.17,1.58)
1
1.39(1.07,1.79)
1.06(0.87,1.29)
1.44(1.00,2.06)
2.16(1.51,3.08)
1
1.17(0.93,1.48)
1.32(1.05,1.67)
1
1.36(1.19,1.57)
1.45(1.24,1.69)
1
1.44(1.26,1.64)
1
1.75(1.50,2.03)
1
0.87(0.75,1.01)
1.02(0.87,1.20)
1
1.12(0.98,1.28)
1
1.97(1.46,2.65)
2.88(2.11,3.95)
1
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1
1.28(0.79,2.09)
1.48(0.95,2.31)
1.41(0.91,2.18)
2.00(1.29,3.08)
1
1.22(1.04,1.43)
P value
interaction* 
 
0.0169
0.015
0.795
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*−Pvalue for testing interaction between country income  and each exposure category
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Education
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Yes
Grip Strength
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Quintile 1
Household Air Pollution
Clean
Solid Fuel
HR
(95%CI) 
 
1
1.29(1.11,1.49)
2.14(1.90,2.42)
1
0.98(0.80,1.18)
0.73(0.63,0.84)
0.80(0.64,1.00)
0.71(0.52,0.98)
1
1.06(0.94,1.19)
1.08(0.93,1.25)
1
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1
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1
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1
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1
1.08(0.90,1.30)
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1
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0.74(0.55,0.99)
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Figure 6 
 
Table 1: Baseline Characteristics of the Study Population Overall and by County Income 
Groups 
 
Factors 
Overall 
N=155,722 
HIC 
N=17,249 
MIC 
N=102,680 
LIC 
N=35,793 
Urban residence 81897(52•6) 12506(72•5) 52134(50•8) 17257(48•2) 
Female 90811(58•3) 9376(54•4) 60822(59•2) 20613(57•6) 
Age: Mean (SD) 50·22( 9•9) 51•60( 9•4) 50·65( 9•7) 48•32(10•3) 
A: Behavioural cluster of risk factors: 
   Tobacco Use – N (%)          
      Current 31821(20·6) 2279(13•3) 21635(21•3) 7907(22•2) 
      Former 17225(11•2) 5261(30•6) 10422(10•2) 1542( 4•3) 
      Never 105387(68•2) 9660(56•2) 69624(68•5) 26103(73•4) 
   Alcohol Use – N (%)          
     Never 108133(71•0) 5253(30•8) 72035(72•3) 30845(86•7) 
     Former 6446( 4•2) 940( 5•5) 4533( 4•5) 973( 2•7) 
     Current: Low 28314(18•6) 7790(45•7) 17770(17•8) 2754( 7•7) 
     Current: Moderate 6466( 4•2) 2333(13•7) 3572( 3•6) 561( 1•6) 
     Current: High 2959( 1•9) 747( 4•4) 1788( 1•8) 424( 1•2) 
   PURE Diet Score –  
   Mean(SD) 
3•94( 1•9) 5•60( 1•6) 4•14( 1•8) 2•53( 1•5) 
   Physical Activity (Met  
   x min/week)  
   – N (%) 
              
     Low: < 600 26691(18•5) 2861(17•9) 17342(17•9) 6488(20•9) 
     Moderate: 600-3000 53489(37•2) 5661(35•4) 37461(38•7) 10367(33•4) 
     High: >3000 63731(44•3) 7471(46•7) 42044(43•4) 14216(45•8) 
   Sodium          
     Urine sodium excretion    
     - Mean g/d (SD) 
4•71( 1•9) 4•06( 1•5) 4•99( 1•9) 3•38( 1•7) 
     Sodium < 4 g/d 37099(36•5) 7717(52•1) 23358(29•9) 6024(69•0) 
     Sodium 4-6 g/d 42226(41•6) 5980(40•4) 34219(43•8) 2027(23•2) 
     Sodium >= 6 g/d 22284(21•9) 1120( 7•6) 20483(26•2) 681( 7•8) 
B: Metabolic cluster of risk factors: 
   Hypertension - N (%) 57303(39•4) 6315(37•9) 40583(42•2) 10405(31•9) 
   SBP (mmHg) – Mean  
   (SD) 
130•89(22•3) 129•11(19•6) 132•67(22•6) 126•58(21•9) 
   DBP (mmHg) – Mean  
   (SD) 
81•71(15•2) 81•46(12•2) 82•26(16•3) 80•24(13•1) 
   Diabetes - N (%) 15900(10•2) 1824(10•6) 9767( 9•5) 4309(12•0) 
   Lipid Measures –  
   (mmol/L) 
    
     Total Cholesterol –  
     Mean (SD) 
4•88( 1•1) 5•29( 1•1) 4•88( 1•1) 4•55( 1•0) 
     LDL Cholesterol –  
     Mean (SD) 
3•07( 1•0) 3•28( 0•9) 3•01( 0•9) 3•16( 1•2) 
     HDL Cholesterol –  
     Mean (SD) 
1•21( 0•4) 1•39( 0•4) 1•19( 0•3) 1•18( 0•4) 
     Non-HDL Cholesterol 3•67( 1•0) 3•88( 1•0) 3•71( 1•0) 3•38( 1•0) 
   BMI - Mean(SD) 25•71( 5•3) 27•81( 5•5) 26•19( 5•1) 23•23( 5•0) 
   Waist to hip ratio  
   (men) - Mean (SD) 
0•85( 0•1) 0•83( 0•1) 0•85( 0•1) 0•84( 0•1) 
   Waist to Hip Ratio    
   (women) - Mean (SD) 
0•91( 0•1) 0•94( 0•1) 0•91( 0•1) 0•91( 0•1) 
   Waist to hip ratio >0•9   
   in men or  >0•85 in  
   women 
73272(50•1) 8865(53•3) 48943(50•7) 15464(46•9) 
C: Socio-economic and psychosocial risk factor cluster: 
   Education – N (%)     
    Primary or less 66353(42•7) 2264(13•2) 44857(43•8) 19232(54•0) 
    Secondary 59081(38•1) 4962(28•8) 42257(41•3) 11862(33•3) 
    Trade/College/   
    University 
29819(19•2) 9977(58•0) 15308(14•9) 4534(12•7) 
   Depression 17450(11•3) 2826(16•4) 10204(10•0) 4420(12•5) 
D: Grip Strength (kg) 
     Mean(SD) 
30•4 (11•1) 35•6 (12•4) 31•0 (11•0) 25•9 ( 9•1) 
E: Air pollution 
   Household air  
   pollution 
   – N (%) 
31447(25•1) 2( 0•0) 20382(23•3) 11063(50•0) 
   Ambient PM2.5 (µg/m3)  
   air pollution 
47•3(32•5) 20•9(32•3) 47•9(29•3) 58•4(34•3) 
SD = standard deviation, PM = particulate matter, HIC=High Income countries, MIC= 
Middle Income countries, LIC= Low income countries 
 
Table 2: Risk of major cardiovascular disease and death associated with 12 modifiable risk 
factors in the overall population. 
 
Exposure 
CVD 
Hazard ratio (95% 
confidence 
intervals) 
Death 
Hazard ratio 
(95% confidence 
intervals) 
A: Behavioral cluster of risk factors: 
   Tobacco use        
     Never (reference)   
     Former 1•19(1•08,1•31) 1•22(1•11,1•34) 
     Current 1•64(1•51,1•77) 1•74(1•61,1•88) 
   Alcohol intake   
     Never (reference)        
     Former 1•08(0•96,1•23) 1•27(1•12,1•43) 
     Current Low 0•77(0•70,0•84) 0•92(0•84,1•01) 
     Current Moderate 0•88(0•77,1•02) 0•89(0•77,1•03) 
     Current High 0•83(0•67,1•02) 1•41(1•20,1•66) 
   PURE diet score   
     Score 5 or higher (reference)    
     Score 3-4 1•07(1•00,1•16) 1•10(1•02,1•19) 
     Score <=2 1•13(1•03,1•24) 1•22(1•11,1•33) 
   Physical activity        
     High activity (reference)   
     Moderate activity 1•11(1•04,1•19) 1•26(1•18,1•35) 
     Low Activity 1•20(1•10,1•30) 1•39(1•28,1•50) 
B: Metabolic cluster of risk factors: 
   Hypertension 2•00(1•87,2•14) 1•40(1•31,1•50) 
   Diabetes 1•74(1•61,1•88) 1•68(1•55,1•81) 
   Non-HDL cholesterol   
    <3.2 (reference)   
     3.2-4.0 1•12(1•04,1•21) 0•87(0•81,0•94) 
     > 4.0 1•31(1•21,1•41) 0•93(0•86,1•00) 
   Waist to hip ratio        
   --WHR M>0.9/W>0.85 1•26(1•18,1•34) 1•13(1•05,1•20) 
C: Socio-economic and psychosocial cluster of risk factors: 
   Education        
     Trade/College/University 
(reference) 
  
     Secondary 1•11(1•01,1•22) 1•15(1•03,1•29) 
     Primary or less 1•37(1•23,1•52) 1•55(1•39,1•74) 
   Depression 1•17(1•05,1•29) 1•31(1•19,1•43) 
D: Grip strength              
   Quintile 5 (reference)   
   Quintile 4 1•12(1•01,1•24) 1•09(0•97,1•23) 
   Quintile 3 1•18(1•07,1•31) 1•16(1•04,1•30) 
   Quintile 2 1•21(1•09,1•35) 1•25(1•11,1•40) 
   Quintile 1 1•36(1•21,1•52) 1•60(1•42,1•79) 
E: Air pollution 
  Household air pollution  
 
1•09(1•00,1•19) 1•24(1•14,1•36) 
Sodium and ambient air pollution results are presented separately. All models for the remaining 
12 individual and household level covariates were mutually adjusted for each risk factor, in 
addition to age, and sex. A variable for each participating PURE center was also included as a 
random effect. HDL = high density lipoproteins, WHR = waist to hip ratio. 
 
Table 3: Rank order for the top 10 risk factors for major CVD and death overall and in high-
, middle, and low-income countries along with their PAFs: 
CVD 
RANK  Overall 
PAF (95% 
Confidence 
Interval) 
HIC 
PAF (95% 
Confidence 
Interval) 
MIC 
PAF (95% 
Confidence  
Interval) 
LIC 
PAF (95%  
Confidence  
Interval) 
1 Hypertension 
22•3 ( 17•4 , 27•2 
) 
High Non-HDL 
cholesterol 
20•7 ( 7•7 , 33•6 ) 
Hypertension 
26•5 (22•2 , 30•9 ) 
Hypertension 
14•3 (7•4 , 21•2 ) 
2 High Non-HDL 
cholesterol 
8•1 (3•1 , 13•2) 
Tobacco Use 
15•7 (3•3 , 28•0 ) 
Low Education 
6•3 (3•0 ,9•5 ) 
High Non-HDL 
cholesterol 
14•2 ( 9•0 , 19•3 ) 
3 Household air 
pollution 
6•9 (4•7 , 9•1)  
Hypertension 
14•6 (6•2 , 23•0 ) 
Tobacco Use 
5•9 ( 2•6 , 9•3 ) 
Household air 
pollution 
12•0 (6•5 , 17•5 ) 
4 Tobacco Use 
6•1 (4•5 , 7•6 ) 
Diabetes 
7•8 (3•9 , 11•7 ) 
Household air 
pollution 
5•2 ( 2•6 , 7•8 ) 
Diabetes 
10•4 (4•7 ,16•2 ) 
5 Poor diet 
6•1 (2•8 , 9•5 ) 
Abdominal obesity 
6•8 ( -6•5 , 20•1 ) 
Abdominal Obesity 
5•2 (1•8 , 8•6 ) 
Poor Diet 
10•0 ( -5•3 , 25•2 ) 
6 Low Education 
5•8 ( 2•8 , 8•8) 
Low Education 
2•0 ( -2•4 , 6•4) 
High Non-HDL 
cholesterol 
5•0 ( 2•0 , 8•1 ) 
Abdominal Obesity 
7•0 ( 0•2 , 13•9 ) 
7 Abdominal 
Obesity 
5•7 ( 1•7 , 9•8) 
Depression 
1•1 ( -3•5 , 5•8) 
Poor Diet 
4•6 (0•9 , 8•3 ) 
Low Education 
6•0 ( -4•5 , 16•5 ) 
8 Diabetes 
5•1 ( 2•9 , 7•4) 
Low Grip Strength 
1•0 ( -4•2 , 6•1) 
Diabetes 
4•0 (2•9 , 5•1 ) 
Tobacco Use 
4•5 ( -1•6 , 10•6) 
9 Low Grip Strength 
3•3 ( 0•9 , 5•7) 
Poor diet 
0•2 ( -6•4 , 6•9 ) 
Low Grip Strength 
3•2 ( 0•5 , 5•9 ) 
Low Physical Activity 
2•2 ( -0•7 , 5•2) 
10 Low Physical 
Activity 
1•5 ( 0•3 , 2•7) 
Excess alcohol 
0•1 ( -5•8 , 6•0) 
Low Physical Activity 
1•7 ( 0•2 , 3•1 ) 
Excess Alcohol 
0•2 ( -1•5 , 2•0 ) 
Mortality 
RANK Overall HIC MIC LIC 
PAF (95% 
Confidence 
Interval) 
PAF (95% 
Confidence 
Interval) 
PAF (95% 
Confidence 
Interval) 
PAF (95% 
Confidence 
Interval) 
1 Low Education 
12•5 ( 10•7 , 14•3 
) 
Tobacco Use 17•9 
(1•2 , 34•6 ) 
Hypertension 
13•2 ( 11•2 , 15•1 ) 
Poor Diet 
19•2 ( 9•0 , 29•4 ) 
2 Tobacco use 
11•3 ( 8•1 , 14•5 ) 
Hypertension 
13•1 ( -7•4 , 33•6 ) 
Tobacco Use 
12•6 ( 8•9 , 16•3 ) 
Low Education 
13•7 ( 7•7 , 19•7 ) 
3 Low grip strength 
11•6 ( 7•3 , 16•0 ) 
Abdominal Obesity 
11•4 ( -6•1 , 28•9 ) 
Low Education 
12•1 ( 6•2 , 18•0 ) 
Low Grip Strength 
10•9 ( 4•4 , 17•5 ) 
4 Poor diet 
11•1 ( 7•7 , 14•6 ) 
Low Education 
7•2 ( 1•7 , 12•7 ) 
Low Grip Strength 
7•9 ( 5•0 , 10•7 ) 
Household  air 
pollution 
9•0 ( 3•7 , 14•2 ) 
5 Hypertension 
8•8 ( 7•6 , 9•9 ) 
Diabetes 
5•9 ( -0•4 , 12•2 ) 
Poor Diet 
6•1 ( -1•1 , 13•2 ) 
Tobacco Use 
7•6 ( 0•7 , 14•5 ) 
6 Household  air 
pollution 
6•6 ( 4•7 , 8•5 ) 
Excess alcohol 
5•5 ( -0•5 , 11•5 ) 
Abdominal Obesity 
4•7 ( 1•3 , 8•0 ) 
Diabetes 
6•7 ( 4•0 , 9•4 ) 
7 Diabetes 
5•5 ( 4•2 , 6•8 ) 
Poor diet 
2•7 ( -3•8 , 9•1 ) 
Diabetes 
4•5 ( 4•1 , 4•8 ) 
Hypertension 
5•6 ( 0•5 , 10•7 ) 
8 Abdominal obesity 
2•8 ( 1•3 , 4•3 ) 
Depression 
2•3 ( -3•0 , 7•6 ) 
Low Physical Activity 
3•0 ( 1•7 , 4•3 ) 
Low Physical Activity 
2•7 ( 0•4 , 5•0 ) 
9 Depression 
2•2 ( 1•4 , 3•0 ) 
Low Grip Strength 
1•6 ( -8•1 , 11•4 ) 
Depression 
1•9 ( 0•6 , 3•2 ) 
Depression 
1•9 ( 0•4 , 3•4 ) 
10 Low physical 
activity 
2•2 ( 1•0 , 3•3 ) 
Household air 
pollution 
0 ( -1•5 , 1•5 ) 
Household  air 
pollution 
1•8 ( -1•8 , 5•3 )  
Excess Alcohol 
1•8 ( 0•5 , 3•1 ) 
 
In our subgroup analysis of country groups stratified by income, estimates for some risk factors 
within each category with very modest effects became more sensitive to changes using different 
analytic approaches. Also, for high-non HDL cholesterol, it is likely that the inverse association 
with all-cause mortality is a result of unmeasured confounding or reverse causality, as this 
observation has been reported in some observational studies, but not in clinical trials. Therefore, 
we limited our results to the 10 largest risk factors for CVD and mortality based on PAFs for each 
outcome as these estimates were the most robust. Sodium was not ranked because it was analyzed 
in a subset of the population. Ambient air pollution was not ranked because it is a community level 
risk factor. HDL = high density lipoprotein, HIC = high income countries, HR = hazard ratio, LIC 
= low income countries, MIC = middle income countries. 
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Table 4: Individual and population level risks associated with ambient and household air 1 
pollution 2 
Outcome Hazard Ratio  
(95% confidence intervals) 
Population Attributable Fraction 
(%) 
      Ambient air 
pollution (per 
10 µg/m3 in 
PM 2.5) 
Indoor air 
pollution 
 (yes vs. no) 
Ambient air 
pollution (> 10 
µg/m3 in 
PM2.5)a 
Indoor air 
pollution  
(yes vs. no) 
All-cause 
mortality 
0•97 (0•96-
0•99) 
1•24(1•14,1•36) na* 6•7% 
CV deaths 1•03 (1•00-
1•05) 
1•27(1•08,1•48) 8•7% 7•9% 
Non-CV deaths 0•95 (0•93-
0•97) 
1•26 (1•13,1•41) na* 5•6% 
Major CVD 1•05 (1•03-
1•07) 
1•09 (1•00,1•19) 13•9% 6•9% 
MI 1•03 (1•00-
1•06) 
1•07 (0•93,1•23) 8•7% 4•6% 
Stroke 1•08 (1•05-
1•11) 
1•09 (0•98,1•21) 21•1% 10•1% 
a PAF calculated using 10 µg/m3 as a counterfactual (based on the World Health Organization 3 
guidelines for PM2.5). PM2.5 analyses were restricted to individuals without CVD at baseline and 4 
with available outdoor PM2.5 estimates for 3 years at baseline. Model adjusted for the following 5 
covariates: age, sex, baseline year, smoking status, alcohol use, physical activity, waist-hip ratio, 6 
PURE diet score, INTERHEART risk score, use of solid fuels for cooking, education level, 7 
household wealth index, occupational class, baseline chronic conditions, use of CVD medication, 8 
hypertension status, urban/rural status, baseline country GDP per person, community lights at 9 
night based on satellite data (as an indicator of local economic activity), national or regional 10 
healthcare access & quality index and community random effect. *Not included as PAF was 11 
neutral or negative, potentially related to residual confounding (refer to results section for further 12 
description). CV = cardiovascular, CVD = cardiovascular disease, PM = particulate matter 13 
 14 
 15 
 16 
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Supplementary Appendices: Modifiable risk factors, cardiovascular disease and mortality in 
155,722 individuals from 21 high-, middle-, and low-income countries. 
 
Supplementary Appendix A: Supplementary Methods: 
 
Appendix A1: PURE Study Participant Selection Methodology as Excerpted from Teo et al. Am 
Heart J. 2009 Jul;158(1):1-7 
 
Selection of Countries 
The choice and number of countries selected in PURE reflects a balance between involving a large 
number of communities in countries at different economic levels, with substantial heterogeneity in social 
and economic circumstances and policies, and the feasibility of centers to successfully achieve long-
term follow-up (see Table S2). Thus, PURE included sites in which investigators are committed to 
collecting good-quality data for a low-budget study over the planned 10-year follow-up period and did 
not aim for a strict proportionate sampling of the entire world. 
  
Selection of Communities 
Within each country, urban and rural communities were selected based on broad guidelines (see 
Guidelines for Selection of Countries, Communities, Households, and Individuals Recruited to PURE). 
A common definition for “community” that is applicable globally is difficult to establish. In PURE, a 
community was defined as a group of people who have common characteristics and reside in a defined 
geographic area. A city or large town was not usually considered a single community, rather 
communities from low-, middle-, and high-income areas were selected from sections of the city and the 
community area defined according to a geographical measure (e.g., a set of contiguous postal code areas 
or a group of streets or a village). The primary sampling unit for rural areas in many countries was the 
village. The reason for inclusion of both urban and rural communities is that for many countries, urban 
and rural environments exhibit distinct characteristics in social and physical environment, and hence, by 
sampling both, we ensured considerable variation in societal factors across PURE communities.  
 
The number of communities selected in each country varied, with the aim to recruit communities with 
substantial heterogeneity in social and economic circumstances balanced against the capacity of local 
investigators to maintain follow-up. In some countries (e.g., India, China, Canada, and Colombia), 
communities from several states/provinces were included to capture regional diversity, in policy, 
socioeconomic status, culture, and physical environment. In other countries (e.g Iran, Poland, Sweden, 
and Zimbabwe), fewer communities were selected. 
 
Selections of Households and Individuals 
Within each community, sampling was designed to achieve a broadly representative sample of that 
community of adults aged between 35 and 70 years (see Table S2). The choice of sampling frame within 
each center was based on both “representativeness” and feasibility of long-term follow-up, following 
broad study guidelines. Once a community was identified, where possible, common and standardized 
approaches were applied to the enumeration of households, identification of individuals, recruitment 
procedures, and data collection.  
 
The method of approaching households differed between regions. For example, in rural areas of India 
and China, a community announcement was made to the village through contact of a community leader, 
followed by in-person door-to-door visits of all households. In contrast, in Canada, initial contact was by 
mail followed by telephone inviting members of the households to a central clinic. Households were 
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eligible if at least 1 member of the household was between the ages of 35 and 70 years and the 
household members intended to continue living in their current home for a further 4 years.   
 
For each approach, at least 3 attempts at contact were made. All individuals within these households 
between 35 and 70 years providing written informed consent were enrolled. When an eligible household 
or eligible individual in a household refused to participate, demographics and self-reported data about 
CVD risk factors, education, and history of CVD, cancers and deaths in the households within the 2 
previous years were recorded. 
 
To ensure standardization and high data quality, we used a comprehensive operations manual, training 
workshops, DVDs, regular communication with study personnel and standardized report forms. We 
entered all data in a customized database programmed with range and consistency checks, which was 
transmitted, electronically to the Population Health Research Institute in Hamilton (Ontario, Canada) 
where further quality checks were implemented. 
 
Guidelines for Selection of Countries, Communities, Households, and Individuals Recruited to 
PURE 
Countries 
 1. High-income countries, middle-income countries, and low-income countries, with the 
bulk of the recruitment from low- and middle-income regions. 
 2. Committed local investigators with experience in recruiting for population studies. 
Communities 
 1. Select both urban and rural communities. Use the national definition of the country to 
determine urban and rural communities. 
 2. Select rural communities that are isolated (distance of >50 km or lack easy access to 
commuter transportation) from urban centers. However, consider ability to process bloods 
samples, e.g., villages in rural developing countries should be within 45-min drive of an 
appropriate facility. 
 3. Define community to a geographical area, e.g., using postal codes, catchment area of 
health service/clinics, census tracts, areas bordered by specific streets or natural borders such 
as a river bank. 
 4. Consider feasibility for long-term follow-up, e.g., for urban communities, choose sites 
that have a stable population such as residential colonies related to specific work sites in 
developing countries. In rural areas, choose villages that have a stable population. Villages at 
greater distance from urban centers are less susceptible to large migration to urban centers. 
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 5. Enlist a community organization to facilitate contact with the community, eg, in urban 
areas, large employers (government and private), insurance companies, clubs, religious 
organizations, clinic or hospital service regions. In rural areas, local authorities such as 
priests or community elders, hospital or clinic, village leader, or local politician. 
Individual 
 1. Broadly representative sampling of adults 35 to 70 years within each community unit. 
 2. Consider feasibility for long-term follow-up when formulating community sampling 
framework, e.g., small percentage random samples of large communities may be more 
difficult to follow-up because they are dispersed by distance. In rural areas of developing 
countries that are not connected by telephone, it may be better to sample entire community 
(i.e., door-to-door systematic sampling). 
 3. The method of approach of households/individuals may differ between sites. In MIC and 
HIC, mail, followed up by phone contact may be the practical first means of contact. In LIC, 
direct household contact through household visits may be the most appropriate means of first 
contact. 
 4. Once recruited, all individuals are invited to a study clinic to complete standardized 
questionnaires and have a standardized set of measurements. 
 
Appendix A2: Standardized Event Definitions in PURE 
Prospective Follow-up for Cardiovascular Events and Mortality: History of disease was collected at 
baseline from every participant with standardized questionnaires regarding history of a) hypertension, b) 
diabetes c) stroke d) angina/myocardial infarction/coronary artery disease e) heart failure f) other heart 
disease.   
Information on specific events (death, myocardial infarction, stroke, heart failure, cancer, 
hospitalizations, new diabetes, injury, tuberculosis, human immunodeficiency viral infections, malaria, 
pneumonia, asthma, chronic obstructive pulmonary disease) were obtained from participants or their 
family members (events were reported by the participants if alive or by a relative if the individual had 
died). This information was adjudicated centrally in each country by trained physicians using 
standardized definitions. Because the PURE study involves urban and rural areas from middle- and low-
income countries, supporting documents to confirm cause of death and/or event varied in degrees of 
completion and availability. In most of middle- and low-income countries there was no central system of 
death or event registration. Therefore, information was obtained about prior medical illness and 
medically certified cause of death where available, and, second, best available information was captured 
from reliable sources in those instances where medical information was not available in order to be able 
to arrive at a probable diagnosis or cause of death. Event documentation was based on information from 
household interviews and medical records, death certificates and other sources. Verbal autopsies were 
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also used to ascertain cause of death in addition to medical records which were reviewed by a health 
professional. This approach has been used in several studies conducted in middle- and low-income 
countries. 
To ensure a standard approach and accuracy for classification of events across all countries and over 
time, the first 100  CVD events (deaths, MI, strokes, heart failure or cancers) for China and India, and 50 
cases for other countries were adjudicated both locally and also by the adjudication chair, and if 
necessary further training was provided. Thereafter, every year, 50 cases for China and India and 25 
cases for each of the remaining countries were adjudicated as above.   
 
FATAL EVENTS 
Cardiovascular Death – Definitions 
01.00 DEATH DUE TO CARDIOVASCULAR EVENTS 
01.10 Sudden unexpected Cardiovascular Death (SCVD) 
Without evidence of other cause of death, death that occurred suddenly and unexpectedly (examples: 
witnessed collapse, persons resuscitated from cardiac arrest who later died) or persons seen alive less 
than 12 hours prior to discovery of death (example persons found dead in his/her bed).  
• SCVD is either definite, probable or possible according to the following characteristics: 
PURE  
Adjudication 
Code 
Event Type 
 
Acceptable 
ICD-10 
codes 
01.11: Definite  One of the following in persons with: 
• known cardiovascular disease, or  
• diabetes with an additional risk factor such as hypertension, 
smoking, dyslipidemia, micro albuminuria, serum creatinine 
50% above upper limit of normal, or 
• 3 of the above risk factors, or 
• 2 of the above risk factors in men aged 60 and more and 
women aged 65 and more  
 
 
 
 
 
 
No ICD-
10 Code 
01.12: 
Probable  
One of the following in persons with: 
• diabetes, or  
• 2 of the above risk factors in men aged less than 60 and in 
women less than 65, or  
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• one of the above risk factor in men aged 60 and more and in 
women aged 65 and more, or 
• typical of chest pain or sudden severe dyspnea of less than 20-
minute duration preceding the event  
01.13: Possible  In persons without risk factor 
For SCVD, the patient was well or had a stable CVD (example stable angina) when last seen alive. 
The event of a sudden death occurring during the hospitalization of MI is considered a fatal MI and 
not sudden death. 
 
01.30 Fatal Myocardial Infarction (MI) 
Symptoms of Myocardial Infarction:  
Typical symptoms or suggestive symptoms of MI according to physician are characterized by severe 
anterior chest pain as tightness, crushing, burning, lasting at least 20 minutes, occurring at rest, or on 
exertion, that may radiate to the arms or neck or jaw and may be associated with dyspnea, diaphoresis 
and nausea. However, death associated with nausea and vomiting with or without chest pain not due to 
another cause may be considered as possible MI if ECG and cardiac markers are not done. These 
symptoms may have occurred the last month before death. 
Fatal myocardial infarction is either definite, probable or possible according to the following 
characteristics: 
PURE  
Adjudication 
Code 
Event Type Acceptable 
ICD-10 
codes 
01.31: Definite  1. Autopsy demonstrating fresh myocardial infarction and/or 
recent coronary occlusion, or 
2. ECG showing new and definite sign of MI (Minnesota code 1-
1-1) or 
3. Symptoms typical or atypical or inadequately described but 
attributed to cardiac origin lasting at least 20 minutes and by 
troponin or cardiac enzymes (CKMB, CK, SGOT, SLDH) 
above center laboratory ULN 
4. ECG with new ischemic changes (new ST 
elevation/depression or T wave inversion ≥ 2 mm) and by 
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troponin or cardiac enzymes (CKMB, CK, SGOT, SLDH) 
above center laboratory ULN 
 
 
 
I21- I22 
01.32: 
Probable  
 
 
1. ECG with sign of probable MI (Minnesota code 1-2-1), or 
2. Typical symptoms lasting at least 20 minutes considered of 
cardiac origin, with only new ST-T changes (new ST 
elevation/depression or T wave inversion ≥ 1 but < 2mm) 
without documented increased cardiac markers or enzyme as 
in PURE definition 1.31 (above), or 
3. Increased cardiac enzymes as in PURE definition 1.31 (above) 
showing a typical pattern of MI as above without symptoms or 
significant ECG changes 
01.33: Possible  1. ECG with sign of possible MI (Minnesota code 1-3-1) or 
2. Typical symptoms or symptoms suggestive of MI according to 
the physician lasting at least 20 minutes without documented 
ECG or cardiac marker.  
 
The Minnesota codes for MI is taken from Rose and Blackburn and published in their book “Evaluation 
Methods of Cardiovascular Disease WHO 1969”. 
• Definite  MI is Q/R ratio ≥1/3 and Q duration ≥ 0.03 second in one of the following leads: I, II, 
V2, 3, 4, 5, 6. (code 1-1-1) 
• Probable MI is Q/R ratio ≥1/3 and Q duration between 0.02 and  0.03 second in one of the 
following leads: I, II, V2, 3, 4, 5, 6. (code 1-2-1) 
• Possible  MI is Q/R ratio between 1/5 and 1/3 and Q duration between 0.02 and  0.03 second in 
one of the following leads: I, II, V2, 3, 4, 5, 6. (code 1-3-1) 
 
01.40 Fatal Stroke  
Fatal stroke is either definite or possible according to the following characteristics: 
PURE  
Adjudication 
Code 
Event Type Acceptable 
ICD-10 
codes 
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01.41: Definite  Stroke death is defined as death within 30 days from an acute focal 
neurological deficit diagnosed by a physician and thought to be of 
vascular origin (without other cause such as brain tumor) with signs 
and symptoms lasting >= 24 hrs. 
Stroke death is also considered if death occurred within 24 hrs. of 
onset of persisting signs and symptoms, or if there is evidence of a 
recent stroke on autopsy. 
N.B. 
• In a subject with a stroke <= 30 days: If death occurred with a 
pneumonia due to possible aspiration, death will be considered 
to be due to stroke.  
• In a subject with a stroke > 30 days:  If death occurred with a 
pneumonia due to possible aspiration, the adjudicator will 
make a decision according to his/her clinical judgment if death 
is related to stroke or not. 
• Subarachnoid hemorrhage death manifested by sudden onset 
headache with/without focal signs and imaging (CT or MRI) 
evidence of bleeding primarily in the subarachnoid space is 
considered a fatal stroke in absence of trauma or brain tumor 
or malformation 
• Subdural hematoma death is not considered as a stroke death 
and may be related to previous trauma or other cause.  
 
 
 
 
 
 
 
 
 
I60- I64, 
I69 
01.43: Possible Death in a participant with a history of sudden onset of focal 
neurological deficit of one or more limbs, loss of vision or slurred 
speech lasting about 24 hours. 
 
01.50 Fatal Congestive Heart Failure 
Fatal congestive heart failure is either definite or possible according to the following characteristics: 
PURE  
Adjudication 
Code 
Event Type Acceptable 
ICD-10 codes 
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01.51: Definite  The diagnosis of congestive heart failure may be an autopsy 
finding in absence of other cause or requires signs (rales, increased 
jugular venous pressure or ankle edema) or symptoms (nocturnal 
paroxysmal dyspnea, dyspnea at rest or ankle edema) of 
congestive heart failure and one or both of the following: 
• radiological signs of pulmonary congestion, 
• treatment of heart failure with diuretics 
 
If sudden death occurred in a patient with chronic severe heart 
failure, it should be adjudicated as fatal congestive heart failure. 
 
 
 
 
 
 
 
I50 
01.52: 
Probable 
Progressive shortness of breath on lying down or at night, 
improving on sitting up AND any of the following signs or 
symptoms: swelling of feet, distension of abdomen, progressive 
cough in a person with known hypertension or a history of 
previous MI/angina or other heart disease 
01.53: Possible  Progressive shortness of breath on lying down or at night, 
improving on sitting up AND any of the following signs or 
symptoms: swelling of feet, distension of abdomen, progressive 
cough 
 
01.60 Death Due to Other Cardiovascular Deaths (other causes [1.10 to 1.50 above] having been 
excluded) 
PURE  
Adjudication 
Code 
Event Type Acceptable 
ICD-10 codes 
01.61 Arterial rupture of aneurysm I71- I72 
01.62 Pulmonary embolism 
NOTE: Death associated with pulmonary embolism occurring 
within 2 weeks after a fracture such as hip, femur should 
attributed to death due to injury. Refer to Injury, Section 6.0 
I26 
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01.63 Arrhythmic death (A-V block, sustained ventricular tachycardia 
in absence of other causes) 
I44- I45, 
I47- I49 
01.64 Death after invasive cardiovascular intervention: a perioperative 
death extending to 30 days after coronary or arterial surgical 
revascularization and to 7 days after a coronary or arterial 
percutaneous dilatation (angioplasty) with or without a stent or an 
invasive diagnostic procedure.      
 
I97 
01.65 Congenital heart disease Q20-Q28 
01.66 Heart valve disease (including rheumatic heart disease) I01, I05- I09, 
I34- I37 
01.67 Endocarditis I33, I38 
01.68 Myocarditis I40 
01.69 Tamponade (pericarditis) I30, I31, I32 
01.70 Other cardiovascular events (Excluding 1.61 to 1.69 above) 
Valid ICD-10 codes would include the following: 
I11, I12, I13, I23, I24, I25, I27, I28, I42, I51, I52, I65-I68, I73, 
I74, I96, I98, I99 (Refer to ICD-10 Listing for associated 
definitions for each code) 
Any valid ‘I’ 
(Cardiovascular) 
ICD-10 code 
that can be 
classified as 
underlying 
cause of death, 
not specified 
above 
 
NON-FATAL EVENTS 
Cardiovascular Events – Definitions 
10.00 NON-FATAL CARDIOVASCULAR EVENTS 
10.10 Non-Periprocedural Myocardial Infarction (MI) 
MI is considered either definite, probable or possible according to the following characteristics: 
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PURE  
Adjudication 
Code 
Event Type 
 
Acceptable 
ICD-10 
codes 
10.11: Definite  1. ECG showing new and definite sign of MI (Minnesota code 1-
1-1) or 
2. Symptoms typical or atypical or inadequately described but 
attributed to cardiac origin lasting at least 20 minutes and by 
troponin or cardiac enzymes (CKMB, CK, SGOT, SLDH) 
above center laboratory ULN 
3. ECG with new ischemic changes (new ST 
elevation/depression or T wave inversion ≥ 2 mm) and by 
troponin or cardiac enzymes (CKMB, CK, SGOT, SLDH) 
above center laboratory ULN 
 
Please note that increased markers may occur in trauma (CK, AST, 
myoglobin and CK MB to a lesser degree); renal insufficiency, heart 
failure, pulmonary embolism (troponin), cardioversion (all)  
 
 
 
 
 
 
 
 
 
 
I21-I22 
10.12: 
Probable  
1. ECG with new and probable sign of MI (Minnesota code 1-2-
1), or 
2. Typical symptoms lasting at least 20 minutes considered of 
cardiac origin, with only new ST-T changes (new ST 
elevation/depression or T wave inversion ≥ 1 but < 2mm) 
without documented increased cardiac markers as in PURE 
definition 10.11 (above), or 
3. Increased cardiac enzymes showing a typical pattern of MI as 
above without symptoms or significant ECG changes. 
10.13: Possible  1. ECG with new and possible sign of MI (Minnesota code 1-3-
1), or 
2. Typical symptoms lasting 20 minutes and more considered to 
be of cardiac origin without documented ECG or cardiac 
marker.  
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10.20 Periprocedural Myocardial Infarction 
PURE  
Adjudication 
Code 
Event Type Acceptable 
ICD-10 
codes 
10.21: Definite  1. ECG showing new and definite sign of MI (Minnesota code 1-
1-1), or 
2. Increased cardiac markers within 48 hours of procedure: 
• percutaneous coronary intervention:  CKMB should be ≥  5 X 
ULN or troponin ≥ 5 X above lower level of necrosis OR > 
20% increase in cardiac markers if elevated at the beginning of 
the procedure in a patient with symptoms suggestive of 
myocardial ischemia 
• Coronary surgery: Increased cardiac markers CKMB should 
be ≥ 10X ULN or troponin ≥ 10X above lower limit of 
necrosis. 
 
 
 
 
 
I21-I22 
 
The Minnesota codes for MI is taken from Rose and Blackburn and published in their book “Evaluation 
Methods of Cardiovascular Disease WHO 1969”. 
• Definite  MI is Q/R ratio ≥1/3 and Q duration ≥ 0.03 second in one of the following leads: I, II, 
V2, 3, 4, 5, 6. (code 1-1-1) 
• Probable MI is Q/R ratio ≥1/3 and Q duration between 0.02 and  0.03 second in one of the 
following leads: I, II, V2, 3, 4, 5, 6. (code 1-2-1) 
• Possible  MI is Q/R ratio between 1/5 and 1/3 and Q duration between 0.02 and  0.03 second in 
one of the following leads: I, II, V2, 3, 4, 5, 6. (code 1-3-1) 
10.30 Stroke/Transient Ischemic Attack (TIA) 
PURE  
Adjudication 
Code 
Event Type Acceptable 
ICD-10 
codes 
10.31: Definite  Stroke is defined as an acute focal neurological deficit diagnosed by a 
physician and thought to be of vascular origin (without other case 
such as brain tumor) with signs and symptoms lasting ≥ 24 hrs.  
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N.B. 
• Subarachnoid hemorrhage manifested by sudden onset 
headache with/without focal signs and imaging (CT or MRI or 
lumbar puncture) showing evidence of bleeding primarily in 
the subarachnoid space is considered a stroke in absence of 
trauma or brain tumor or malformation 
 
• Subdural hematoma is not considered as a stroke and may be 
related to previous trauma or other cause. 
I60-I64, 
I69 
10.33: Possible  Stroke is possible if there is a history of sudden onset of focal 
neurological deficit of one or more limbs, loss of vision or slurred 
speech lasting about 24 hours or more 
10.34: TIA The diagnosis of TIA requires the presence of acute focal neurological 
deficit thought to be of vascular origin with signs and symptoms 
lasting less than 24 hours 
G45 
 
10.40 Congestive Heart Failure 
PURE  
Adjudication 
Code 
Event Type Acceptable 
ICD-10 
codes 
10.41: Definite  The diagnosis of congestive heart failure requires signs (rales, 
increased jugular venous pressure or ankle edema) or symptoms 
(nocturnal paroxysmal dyspnea, dyspnea at rest or ankle edema) of 
congestive heart failure and one or both of the following: 
• radiological signs of pulmonary congestion, 
• Treatment of heart failure with diuretics.   
 
 
 
 
 
 
 
I50 
10.42: 
Probable 
Progressive shortness of breath on lying down or at night, improving 
on sitting up AND any of the following signs or symptoms: swelling 
of feet, distension of abdomen, progressive cough in a person with 
known hypertension or a history of previous MI/angina or other heart 
disease 
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10.43: Possible  
 
Congestive heart failure is considered possible when there is 
progressive shortness of breath on lying down or at night, improving 
on sitting up AND any of the following signs or symptoms: swelling 
of feet, distension of abdomen, progressive cough  
 
Appendix A3: Assumptions examined in Cox Frailty Models: The proportionality assumption of the 
Cox model was assessed by visual inspection of (1) initial stratified Kaplan-Meier curves by the variables 
in the model, and by (2) log(-log survival) vs log time plots after fitting Cox models. We did not see any 
meaningful departures from the proportionality assumption. 
 
We examined the residual heterogeneity, assessing the proportional reduction in the covariance parameter 
from the null model with inclusion of frailty terms (i.e. the application of random effects intercepts in the 
cox frailty model). Residual heterogeneity was reduced by 24% at the country level and when we included 
a frailty term at the community level, it was reduced by a further 54% in the final Cox models. 
 
Appendix A4: Note on sodium analysis: Because information on urinary sodium was available in only 
113,078 participants, its associations with CVD and mortality were calculated separately using Cox frailty 
models mutually adjusted for age, sex, and all  risk factors other than hypertension, which is considered 
to be the primary mediating factor for the effects of sodium on CVD and mortality. Sodium analyses were 
also adjusted by China versus other countries as a covariate because of the clustering of communities with 
high sodium excretion values in China. Sodium excretion between 4-6g/day was used as the reference 
category in our hazard ratio calculations because in our previous analyses this range was associated with 
the lowest risk.  
 
Since we were primary interested in estimating the PAF related to high sodium excretion, and we did not 
consider the effects of low sodium excretion (i.e. less than 4 g/day) with increased CVD and mortality. 
Therefore, participants with a sodium of <4g/day were excluded in the PAF calculation. Therefore the 
impact on CVD and deaths of a downward shift in the entire distribution of sodium intake in the whole 
population may be overestimated by our approach.  
Appendix A5: Note on PM2.5 ambient air pollution: Since ambient PM2.5 air pollution was estimated 
at the community level, the associations of PM2.5 with CVD and mortality were also calculated separately 
after adjusting for both individual and additional community level risk factors. The model was adjusted 
for the following covariates: age, sex, baseline year, smoking status, alcohol use, physical activity, waist-
hip ratio, PURE diet score, INTERHEART risk score, use of solid fuels for cooking, education level, 
household wealth index, occupational class, baseline chronic conditions, use of CVD medication, 
hypertension status, urban/rural status, baseline country GDP per person, community lights at night 
satellite data (indicator of local economic activity), national or regional healthcare access & quality index 
and community random effect. 
 
We estimated a separate PAF using the fully adjusted linear HRs and the PM2.5 exposure distribution 
for PURE participants. The PAF was calculated using 10 µg/m3 as a counterfactual (based on the World 
Health Organization guidelines for PM2.5).Therefore, the PAFs for ambient air pollution is not strictly 
comparable to the estimates for the other risk factors. 
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Appendix A6: Note on calculation of the Average Population Attributable Fractions: Mutually 
adjusted, average population attributable fractions (APAFs) and their 95% confidence intervals were 
calculated using the approach described by Eide and Olaf. In this approach, APAF for each risk factor are 
determined using logistic regression, all risk factors of interest are added to the model in every possible 
order, and the average of all PAFs are then calculated using the R package called ‘averisk’ developed by 
Ferguson et. al. Estimates of PAF were further adjusted for age, sex and urban/rural location. This APAF 
calculation allows for an estimation of the individual contribution of each risk factor (or group of risk 
factors) to the overall PAF, and generally provides a smaller estimate for PAF for individual risk factors 
than more conventional methods used by GBD, and in INTEREART and INTERSTROKE, for which the 
sum of individual risk factor PAFs exceed the cumulative PAF. The ‘averisk’ package also computes 
confidence intervals based on Monte Carlo simulation. Consistent with our hazard ratio calculations, PAFs 
for 12 risk factors (excluding sodium and ambient air pollution) were calculated together using a single 
model. For sodium excretion was only available in two-thirds of the study population, intake and air 
pollution was analyzed as a community level variable, and for these reasons both hazard ratios and PAFs 
were calculated separately from the other 12 risk factors 
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Supplementary Appendix B: Supplementary Tables and Figures:  
Appendix B, Table 1: List of 21 countries participating in phase 1 and 2 of PURE, and number of 
participants eligible, enrolled, included in the analysis 
Country Name 
(grouped by 
county income 
status) 
Number of 
participants 
approached that 
were eligible to 
participate in 
core study 
Number of 
participants 
who consented 
for core study 
Number of  
participants in the 
current analysis* 
HIC 23039 18105 (78.6%) 17249 (95.3%) 
  UAE 2158 1498 1427 
  Sweden 5243 4152 3990 
  Canada 13038 10409 9855 
  Saudi Arabia 2600 2046 1977 
    
MIC 150838 110905 (73.5%) 102680 (92.6%) 
  China 63878 47534 44300 
  South Africa 7647 4541 3882 
  Colombia 10904 7490 7258 
  Brazil 8000 6075 5662 
  Chile 4787 3573 3473 
  Iran 7321 6013 5654 
  Argentina 9062 7514 7242 
  Poland 2577 1951 1896 
  Malaysia 20834 15377 15347 
  Turkey 5196 4221 3761 
  Palestine 3062 1634 1554 
  Philippines** 7570 4982 2651 
    
LIC 61303 38058 (62.1%) 35793 (94.0%) 
  India 49908 29168 28204 
  Zimbabwe 1700 1213 1190 
  Bangladesh 3461 2934 2856 
  Pakistan 3093 2714 1621 
  Tanzania 3141 2029 1922 
    
All Countries 235180 167068 (71.0%) 155722 (93.2%) 
 
*Analyses were limited to participants with at least one follow-up visit and without a prior history of CVD 
** In Philippines, only 2331 had reached the time point for the first follow-up, which is ongoing. 
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Appendix B, Table 2: Summary of modifiable risk factors  
Risk Factor Definition or method of 
measurement 
Risk category 
used for 
calculation of 
PAF 
Reference category 
used for 
calculation of PAF 
Behavioural cluster of risk factors: 
Tobacco use Self-reported tobacco 
consumption using a standard 
tobacco use frequency 
questionnaire,   categorized as 
never, former or current.  
History of 
current or former 
tobacco use 
No history of 
tobacco use 
Alcohol1 Self-reported alcohol 
consumption using a standard 
alcohol consumption frequency 
questionnaire. Consumption was 
categorized as former, never and 
current. Current consumption is 
further categorized as low (<=7 
drinks/week), moderate (8-14 
drinks/week in women or 8-21 
drinks/week in men), or high-
consumption (> 14 drinks/week in 
women or >21 drinks/week in 
men). 
Excess alcohol 
use defined as 
either high 
current use or 
former use 
No history of 
alcohol 
consumption, low 
current use, or 
moderate current 
use. 
Diet2–4 Diet was measured using country 
specific, food frequency dietary 
questionnaires (FFQ). Using 
these, a comprehensive diet score 
was created based on  eight food 
types  associated with a lower risk 
of CVD or mortality in PURE: 
fruits, vegetables, legumes, nuts, 
fish, dairy, unprocessed red meat 
and poultry; with each  classified 
into high-consumption (1 point) 
or low-consumption (0 points) 
based on the median amount 
consumed in PURE (in 
Diet score < 4 Diet score > 5** 
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grams/day), then added to a final 
score (with lower scores 
representing a lower quality diet) 
Physical 
activity5 
Physical activity was measured 
using the  International Physical 
Activity Questionnaire, and 
classified as low (<600 metabolic 
equivalents [MET] × minutes per 
week or <150 minutes per week of 
moderate intensity physical 
activity), moderate (600–3000 
MET × minutes or 150–750 
minutes per week) or high (>3000 
MET × minutes or >750 minutes 
per week) 
Low physical 
activity level 
Moderate or high 
physical activity** 
Urine sodium 
excretion6,7 
Urine sodium excretion was 
estimated by the Kawasaki 
formula using morning fasting 
urine samples. 
Estimated urine 
sodium excretion 
> 6g /day 
Estimated urine 
sodium excretion < 
6g/day 
Metabolic cluster of risk factors: 
Hypertension Blood pressure was measured in 
all participants at baseline, and 
hypertension was defined as a 
systolic blood pressure > 140 
mmHg, a self-reported history of 
hypertension, or treatment with 
anti-hypertensive medications.  
Definition of 
hypertension 
was met  
Definition of 
hypertension was 
not met 
Diabetes Diabetes was defined as either a  
fasting glucose > 7 mmol/dl or 
self-reported history of diabetes, 
on treatment for diabetes. 
Definition of 
diabetes was met 
Definition of 
diabetes was not 
met 
Non-HDL 
cholesterol8 
Total cholesterol minus HDL, 
measured using fasting lipid 
values 
Highest two 
tertiles, 
corresponding to 
a value of >3.2 
mmol/L 
Lowest tertile of 
TC-HDL 
Abdominal 
obesity 
Waist and hip circumference was 
measured routinely in participants 
at baseline, and used to calculate 
the waist to hip ratio (WHR) 
WHR > 0.9 in 
men or 0.85 in 
women* 
WHR < 0.9 in men 
or 0.85 in women 
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Socio-economic and psychosocial cluster of risk factors: 
Education9 Education was self-reported, and 
classified as low (primary 
education level or less), 
intermediate (secondary school 
education) or high (college, trade 
school, or university education) 
Low education Moderate or high 
education** 
Symptoms of 
Depression10,11 
 Symptoms of depression were 
reported based on adapted version 
of the Short-Form Composite 
International Diagnostic Interview 
(CIDI-SF) for major depressive 
disorders, using an 8 point 
depression score based self-
reported symptoms associated 
with depression. Symptoms 
consistent with depression was 
defined as a score > 5 
Symptoms 
consistent with 
depression 
No depression 
Grip strength12 Measured using JAMAR 
dynamometer  
Lowest two 
quintiles of grip 
strength 
Highest three 
quintiles of grip 
strength** 
Air pollution cluster of risk factors: 
Household air 
pollution from 
solid fuel use for 
cooking 
      
      
Self-reported primary use of solid 
fuels (i.e. charcoal, coal, wood, 
agriculture/crop, animal dung, 
shrub/grass) for cooking 
Primary use of 
any solid fuel) 
Primary use of gas 
or electricity for 
cooking  
Fine particulate 
matter (PM)2.5 
ambient air 
pollution 
3-year average PM2.5 
concentration assigned to each 
PURE community of residence. 
Please refer to main text for details 
on method of measurement. 
Community 
level exposure > 
10 µg/m3 * 
Community level 
exposure < 10 
µg/m3  
Prior publications from INTERHEART and PURE by Rosengren et al. demonstrated that education level 
was superior to other markers of socioeconomic status such as wealth index and so only education was 
used in this analysis as a marker of socio-economic status.9 *Thresholds for waist to hip ratio and PM2.5 
ambient air pollution were selected based on WHO criteria.13,14 ** 
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For several risk factors where the associated risk was along a continuum, choosing extreme 
counterfactuals or reference values would inflate their impact by a modest degree, but  would  be difficult 
to  achieve in any population based strategy (i.e. shifting all individuals to a college/university of trade 
school education, or shifting all individuals to a high physical activity level). Therefore, we considered 
more conservative reference categories for our primary analyses.  
 
For alcohol, we observed that high and former alcohol consumption were both associated with higher risk 
of mortality, suggesting that in the former group, participants stopped alcohol consumption after suffering 
the adverse health effects of alcohol. Therefore, our risk group for calculation of the PAF related to alcohol 
combined the harmful effects from former and high alcohol consumption. 
 
For sodium intakes less than 4 g/d was associated with higher mortality and CVD compared to 4 to 
6g/d.We excluded these with low sodium as the implications of the above findings is unclear. Inclusion 
of the group with low sodium would counterbalance the effects of increased risks of sodium >6 g/d and 
would essentially nullify any potential excess of sodium as a risk factor. 
 
 
Appendix B, Table 3: Comparison of different lipid markers with the risk of major CVD 
Lipid 
measurement Hazard ratio (95% confidence interval) 
 Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
Total 
cholesterol Reference 
1.11 
(1.00,1.23) 
1.08 
(0.97,1.20) 
1.22 
(1.10,1.35) 
1.35 
(1.22,1.51) 
Non-HDL  
(total 
cholesterol – 
HDL) 
Reference 
1.23 
(1.10,1.37) 
1.19 
(1.07,1.33) 
1.30 
(1.17,1.45) 
1.50 
(1.34,1.67) 
LDL 
cholesterol Reference 
1.04 
(0.93,1.15) 
1.07 
(0.96,1.18) 
1.05 
(0.95,1.17) 
1.32 
(1.19,1.47) 
Total 
cholesterol 
/HDL ratio 
Reference 
1.06 
(0.95,1.19) 
1.14 
(1.03,1.27) 
1.11 
(0.99,1.24) 
1.40 
(1.26,1.56) 
HDL = high density lipoprotein, LDL = low density lipoprotein 
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Appendix B, Table 4: Summary of levels of completeness of  data for each risk factor 
 Overall HIC MIC LIC 
Sample size 155722 17249 102680 35793 
 
Risk factor of 
interest 
Number (%) of participants with complete data 
Hypertension 145357(93.3) 16641(96.5) 96081(93.6) 32635(91.2) 
Diabetes 155722( 100) 17249( 100) 102680( 100) 35793(100) 
Non-HDL 
cholesterol 
120148(77.2) 15538(90.1) 82896(80.7) 21714(60.7) 
Waist to hip ratio 146125(93.8) 16633(96.4) 96509(94.0) 32983(92.1) 
Tobacco use 154433(99.2) 17200(99.7) 101681(99.0) 35552(99.3) 
Alcohol 
consumption 
152318(97.8) 17063(98.9) 99698(97.1) 35557(99.3) 
Diet Score 141164(90.7) 16293(94.5) 92720(90.3) 32151(89.8) 
Physical activity 143911(92.4) 15993(92.7) 96847(94.3) 31071(86.8) 
Sodium excretion 101609(65.3) 14817(85.9) 78060(76.0) 8732(24.4)* 
Education 155253(99.7) 17203(99.7) 102422(99.7) 35628(99.5) 
Depression 154316(99.1) 17189(99.7) 101871(99.2) 35256(98.5) 
Grip strength 141843(91.1) 16221(94.0) 94742(92.3) 30880(86.3) 
Household air 
pollution from 
solid fuel use for 
cooking 
125460(80.6) 15701(91.0) 87616(85.3) 22143(61.9) 
PM2.5 level 154646(99.3) 16744(97.1) 102236(99.6) 35666(99.6) 
*All stored samples in India degraded during storage and so were not analyzed. HDL = high density 
lipoprotein.  
 
Appendix B, Table 5: Total number of events, and age and sex standardized event rates per 1000 
person years: Overall and by Country Income Status 
Event Overall 
(rate per 1000  
person years) 
HIC 
(rate per 1000  
person years) 
MIC 
(rate per 1000  
person years) 
LIC 
(rate per 1000  
person years) 
CVD 7980 ( 4.57) 624 ( 2.87) 5167 ( 4.62) 2189 ( 5.22) 
MI 3559 ( 2.08) 307 ( 1.48) 1909 ( 1.75) 1343 ( 3.25) 
Stroke 3577 ( 1.99) 237 ( 1.05) 2671 ( 2.34) 669 ( 1.52) 
All-Cause Mortality 10234 ( 5.44) 501 ( 2.00) 5543 ( 4.70) 4190 ( 9.13) 
CV Mortality 2917 ( 1.51) 75 ( 0.31) 1613 ( 1.32) 1229 ( 2.67) 
Non-CV Mortality 7317 ( 3.93) 426 ( 1.69) 3930 ( 3.38) 2961 ( 6.46) 
CVD = cardiovascular disease, MI = myocardial infarction  
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Supplementary Figure 1: Consort Diagram of Participants Included in the Current Analysis 
 
 
 
 
 
 
 
22 
 
Supplementary Appendix C: Funding Support, PURE Investigators and Primary Country Based 
Institutions 
Funding/Support: 
Dr. S. Yusuf is supported by the Marion W Burke endowed chair of the Heart and Stroke Foundation of 
Ontario. 
The PURE study is an investigator-initiated study that is funded by the Population Health Research 
Institute, Hamilton Health Sciences Research Institute (HHSRI), the Canadian Institutes of Health 
Research, Heart and Stroke Foundation of Ontario, Support from Canadian Institutes of Health 
Research’s Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit, as well as 
the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several 
pharmaceutical companies [with major contributions from AstraZeneca (Canada), Sanofi-Aventis 
(France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, and GlaxoSmithKline], 
and additional contributions from Novartis and King Pharma and from various national or local 
organisations in participating countries.  
 
These include: Argentina: Fundacion ECLA (Estudios Clínicos Latino America) ; Bangladesh: 
Independent University, Bangladesh and Mitra and Associates; Brazil: Unilever Health Institute, Brazil; 
Canada: Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; 
Chile: Universidad de la Frontera; China: National Center for Cardiovascular Diseases and ThinkTank 
Research Center for Health Development; Colombia: Colciencias (grant 6566-04-18062 and  grant 
6517-777-58228); India: Indian Council of Medical Research; Malaysia: Ministry of Science, 
Technology and Innovation of Malaysia (grant number: 100-IRDC/BIOTEK 16/6/21 [13/2007], and 07-
05-IFN-BPH 010), Ministry of Higher Education of Malaysia (grant number: 600-RMI/LRGS/5/3 
[2/2011]), Universiti Teknologi MARA, Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-
2010); occupied Palestinian territory: the United Nations Relief and Works Agency for Palestine 
Refugees in the Near East, occupied Palestinian territory; International Development Research Centre, 
Canada; Philippines: Philippine Council for Health Research and Development; Poland: Polish 
Ministry of Science and Higher Education (grant number: 290/W-PURE/2008/0), Wroclaw Medical 
University; Saudi Arabia: Saudi Heart Association, Saudi Gastroenterology Association, 
Dr.Mohammad Alfagih Hospital, The Deanship of Scientific Research at King Saud University, Riyadh, 
Saudi Arabia (Research group number: RG -1436-013); South Africa: The North-West University, SA 
and Netherlands Programme for Alternative Development, National Research Foundation, Medical 
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Research Council of South Africa, The South Africa Sugar Association, Faculty of Community and 
Health Sciences; Sweden: Grants from the Swedish state under the Agreement concerning research and 
education of doctors; the Swedish Heart and Lung Foundation; the Swedish Research Council; the 
Swedish Council for Health, Working Life and Welfare, King Gustaf V:s and Queen Victoria 
Freemason’s Foundation, AFA Insurance; Turkey: Metabolic Syndrome Society, AstraZeneca, Sanofi 
Aventis; United Arab Emirates: Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical 
Sciences and Dubai Health Authority, Dubai. 
 
Role of Sponsor: The external funders and sponsors had no role in the design and conduct of the study; 
in the collection, analysis, and interpretation of the data; in the preparation, review, or approval of the 
manuscript; or in the decision to submit the manuscript for publication. 
 
PURE Project Office Staff, National Coordinators, Investigators, and Key Staff:  
 
Project office (Population Health Research Institute, Hamilton Health Sciences and McMaster 
University, Hamilton, Canada):  S Yusuf* (Principal Investigator). 
S Rangarajan (Program Manager); K K Teo, S S Anand, C K Chow, M O’Donnell, A Mente, D Leong, 
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Ren Bing, Sun Yi, Wang Wei, Wang Yang, Yang Jun, Zhai Yi, Zhang Hongye, Zhao Xiuwen,Zhu 
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Sotomayor, F Manzur, H Garcia, G Sanchez, F Cotes, A Rico, M Duran, C Torres; India: Bangalore - 
P Mony *, M Vaz*, S Swaminathan, AV Bharathi, K Shankar, A V Kurpad, K G Jayachitra, H A L 
Hospital, AR Raju, S Niramala, V Hemalatha, K Murali, C Balaji, A Janaki, K Amaranadh, P 
Vijayalakshmi, Chennai - V Mohan*, R M Anjana, M Deepa, K Parthiban, L Dhanasekaran, SK 
Sundaram, M Rajalakshmi, P Rajaneesh, K Munusamy, M Anitha, S Hemavathy, T 
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Mohamed, A Jamaludin, Z Rahim; Occupied Palestinian Territory: R Khatib*, U Khammash, R 
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Ferus, B Regulska-Ilow, D Różańska, M Wolyniec; Saudi Arabia: KF AlHabib*, M Alshamiri, HB 
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South Africa Faculty of Health Science 
North-West University 
Potchefstroom Campus 
University of the Western Cape 
Department of Dietetics and Nutrition 
Private Bag X17, 7535 
Bellville, South Africa 
Zimbabwe University of Zimbabwe 
College of Health Sciences 
Physiology Department 
Harare, Zimbabwe 
Tanzania Pamoja Tunaweza Women Center, Moshi, Tanzania 
Division of Nephrology, Department of Medicine 
Queen's University 
China National Centre for Cardiovascular Diseases 
Cardiovascular Institute & Fuwai Hospital 
Chinese Academy of Medical Sciences 
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167, Bei Li Shi Lu, Beijing, China 
Fuwai Hospital 
167 Beilishi Rd. Xicheng District 
Beijing. 100037 China 
Philippines University of Philippines, Section of Adult Medicine & Medical 
Research Unit, Manila, Philippines 
Pakistan Department of Community Health Sciences and Medicine 
Aga Khan University 
Stadium Road, P.O Box 3500 
Karachi Pakistan 
India  St John's Medical College and Research Institute 
Bangalore 560034, India 
Madras Diabetes Research Foundation & 
Dr. Mohan’s Diabetes Specialities Centre, Chennai 
Eternal Heart Care Centre and Research Institute, Jaipur 
Health Action by People, 
Thiruvananthapuram, Kerala, 695011 INDIA 
School of Public Health, Post Graduate Institute of Medical Education 
& Research, Chandigarh (India) 
Bangladesh Independent University, Bangladesh 
Bashundhara, Dhaka 
Bangladesh 
Malaysia Universiti Teknologi MARA, Sungai Buloh, Selangor, Malaysia AND        
UCSI University, Cheras, Selangor, Malaysia 
Department of Community Health. Faculty of Medicine. University 
Kebangsaan Malaysia. Kuala Lumpur. Malaysia 
Poland Wroclaw Medical University 
Department of Internal Medicine; Department of Social Medicine 
Borowska 213 street; 50- 556 Wroclaw, Poland 
Department of Epidemiology, 
The Maria Skłodowska-Curie Memorial Cancer Center and Institute of 
Oncology 
02-034 Warsaw, 15B Wawelska str. 
Poland 
Sweden Sahlgrenska Academy 
University of Gothenburg 
Sweden 
Russia Research Institute for Complex Issues of Cardiovascular Diseases, 
Kemerovo, Russia 
 
Institute For Medical Education, Yaroslav-the-Wise Novgorod State 
University Ministry of Education and Science of the Russian 
Federation 
Russia, Saint-Petersburg, 197022, 
Karpovka river emb., Bld.13, office 28 
Turkey Istanbul Medeniyet University 
Istanbul, Turkey 
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Iran Isfahan Cardiovascular Research Center, Isfahan Research Institute 
Isfahan University of Medical Sciences, Isfahan, Iran 
UAE Dubai Medical University, Hatta Hospital, Dubai Health Authority,  
Dubai, United Arab Emirates 
Saudi Arabia Department of Cardiac Sciences, King Fahad Cardiac Center  
College of Medicine  
King Saud University  
Riyadh, Saudi Arabia  
Palestine Institute of Community and Public Health, Birzeit University, 
Ramallah, occupied Palestinian territory 
Kazakhstan Research Institute of Cardiology & Internal Diseases, Almaty, 
Kazakhstan 
Kyrgyzstan Kyrgyz Society of Cardiology, National Center of Cardiology and 
Internal Disease, Bishkek, Kyrgyzstan 
Canada Université Laval Institut universitaire de cardiologie et de pneumologie 
de Québec, Quebec 
Canada G1V 4G5 
Simon Fraser University, 
Dept. of Biomedical Physiology & Kinesiology, BC, Canada 
Department of Medicine,  
University of Ottawa,  
Ottawa, Canada 
Population Health Research Institute, McMaster University, Hamilton 
Health Sciences, Hamilton, Ontario, Canada 
Argentina Estudios Clinicos Latinoamerica ECLA 
Rosario, Santa Fe 
Argentina 
 
Department of Chronic Diseases 
South American Center of Excellence for Cardiovascular Health 
(CESCAS) 
Institute for Clinical Effectiveness and Health Policy (IECS) 
Brazil Dante Pazzanese Institute of Cardiology;  
Hospital Alemao Oswaldo Cruz 
Sao Paulo, SP Brazil 
Colombia Facultad de Ciencias de la Salud, Universidad de Santander (UDES), 
Bucaramanga, Santander,  
Fundacion Oftalmologica de Santander (FOSCAL) 
Floridablanca-Santander, Colombia 
Chile Universidad de La Frontera 
Temuco, Chile 
Ecuador  
Facultad de Ciencias de la Salud Eugenio Espejo 
Universidad Tecnológica Equinoccial 
Dirección: Av. Mariscal Sucre s/n y Av. Mariana de Jesús, Quito 
Ecuador 
Peru CRONICAS Centro de Excelencia en Enfermedades Crónicas | 
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www.cronicas-upch.pe  
Universidad Peruana Cayetano Heredia | www.upch.edu.pe 
Av. Armendáriz 497, Miraflores, Lima 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Appendix References: 
1 Smyth A, Teo KK, Rangarajan S, et al. Alcohol consumption and cardiovascular disease, cancer, 
injury, admission to hospital, and mortality: a prospective cohort study. Lancet 2015; 386: 1945–54. 
2 Miller V, Mente A, Dehghan M, et al. Fruit, vegetable, and legume intake, and cardiovascular 
disease and deaths in 18 countries (PURE): a prospective cohort study. Lancet 2017; 390: 2037–49. 
 
 
29 
 
3 Dehghan M, Mente A, Zhang X, et al. Associations of fats and carbohydrate intake with 
cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort 
study. Lancet 2017; 390: 2050–62. 
4 Dehghan M, Mente A, Rangarajan S, et al. Association of dairy intake with cardiovascular 
disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet 
2018; 392: 2288–97. 
5 Lear SA, Hu W, Rangarajan S, et al. The effect of physical activity on mortality and 
cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income 
countries: the PURE study. Lancet 2017; 390: 2643–54. 
6 Mente A, O’Donnell MJ, Rangarajan S, et al. Association of urinary sodium and potassium 
excretion with blood pressure. N Engl J Med 2014; 371: 601–11. 
7 Mente A, O’Donnell MJ, Dagenais G, et al. Validation and comparison of three formulae to 
estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h 
measures in 11 countries. J Hypertens 2014; 32: 1005–14; discussion 1015. 
8 Mente A, Dehghan M, Rangarajan S, et al. Association of dietary nutrients with blood lipids and 
blood pressure in 18 countries: a cross-sectional analysis from the PURE study. Lancet Diabetes 
Endocrinol 2017; 5: 774–87. 
9 Rosengren A, Smyth A, Rangarajan S, et al. Socioeconomic status and risk of cardiovascular 
disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural 
Epidemiologic (PURE) study. Lancet Glob Health 2019; 7: e748–60. 
10 Kessler RC, Ustün TB. The World Mental Health (WMH) Survey Initiative Version of the 
World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods 
Psychiatr Res 2004; 13: 93–121. 
11 Wittchen HU. Reliability and validity studies of the WHO--Composite International Diagnostic 
Interview (CIDI): a critical review. J Psychiatr Res 1994; 28: 57–84. 
12 Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the 
Prospective Urban Rural Epidemiology (PURE) study. Lancet 2015; 386: 266–73. 
13 World Health Organization. Waist circumference and waist-hip ratio : report of a WHO expert 
consultation, Geneva, December 2008. World Health Organization. . 
14 World Health Orgainization. WHO Air quality guidelines for particulate matter, ozone, nitrogen 
dioxide and sulfur dioxide Global update 2005 Summary of risk assessment. Geneva, 2006. World 
Health Organization. . 
 
